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Summary 
The Security Forces Hospital, Saudi Arabia analyses approximately 10,000 urine samples 
per year. One of the main problems with urine sample collection is the possibility of 
adulteration. It has been found that 2-3 % of samples have had attempts at adulteration, 
usually by adding water. In cases of suspected adulteration, the possibility of analysing a 
hair sample in conjunction with the corresponding urine sample would be beneficial to 
confirm the validity of the specimen results. From available statistical records in Security 
Forces Hospital, Saudi Arabia [1], the most common drugs of abuse used were 
amfetamines and cannabinoids. These represent about 80-90% of total positive results of 
drugs of abuse. The purpose of this study was to develop a single method to analyse these 
drugs in hair and to apply this to case samples received from The Security Forces Hospital, 
Saudi Arabia. 
First of all, mass fragments and retention times for arnfetamines and cannabinoids were 
identified by GC-MS using derivatisation agents, PFPA / ethyl acetate (2: 1 v/v) and PFPA 
/ PFPOH (1: 0.75 v/v) for arnfetamines and cannabinoids, respectively. The results 
showed good peak shape, good chromatographic resolution and good sensitivity for 
amfetamine (AF), methamfetamine (MA), 3,4-Methylenedioxyamfetainine (MDA ), 3,4- 
Methylenedioxymethamfetamine (MDMA), 3,4- Methylenedioxyethylamfetamine 
(MDEA), A? -tetrahydrocannabinol (A? -THQ and 11-nor-9-carboxy-A? - 
tetrahydrocannabinol (A? -THC-COOH) compounds. 
The comparison of the efficiency of four different pre-treatment methods (enzymatic, 
alkaline, acid and methanol) to extract AF, MA, MDA, MDMA, MDEA, 2 -THC and 
2 
-THC-COOH from hair samples obtained from known arnfetarnines and cannabinoids 
abusers was investigated. Each method was followed by SPE, derivatisation and detection 
using gas-chromatography mass-spectrometry. The method giving the best recovery for 
the detection and quantification of cannabinoids and amfetamines simultaneously was to 
be selected and fully validated. 
The preliminary results demonstrated difficulty with the cannabinoids recovery and the 
lower concentrations of standards were not detected using any of the pre-treatment 
methods. Consequently, the calibration curves for all pre-treatment methods could not be 
plotted and the initial method was deemed insufficiently sensitive for cannabinoid 
detection purposes. In order to obtain a better recovery of the cannabinoids, parameters in 
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the method were modified. Four different eluents were compared for the cannabinoids; 
acetone /chlorofon-n (1: 1 v/v), hexane / EtOAc (9: 1 v/v), hexane / EtOAc (8: 2 v/v) and 
methanol using alkaline pre-treatment and the pH of the phosphate buffer was also 
changed (pH5,6,7 and 8). 
However, the problem still persisted with the cannabinoids recovery. Meanwhile, the 
amfetamines concentration showed no significant change throughout this investigation. 
As a result of the poor cannabinoids recovery, only the amfetamines were investigated. 
For the comparison study, only one hair sample positive for amfetamine was available so 
the pre-treatment comparison study was based on the recovery of AF using the four pre- 
treatment methods. 
The positive hair sample was separated into portions and pre-treatment methods, alkaline 
(lM NaOH), fl-Glucuronidase (helix pomatia), methanol (MeOH) and acid (0.1M HCI) 
were used on these and compared. The best recovery for amfetamine was obtained using 
the fl-glucuronidase pre-treatment method and this extract was also found to be cleaner 
than the alkaline and methanol pre-treatments. fl-glucuronidase pre-treatment was selected 
as the method of choice for the extraction of amfetamine content in hair. The method was 
validated to include linearity, recovery, intra- and inter-day precision, limit of quantitation 
(LOQ) and limit of detection (LOD) for all five amfetainine compounds. The method was 
shown to be reliable and robust for these substances. 
The stability of AF in hair was investigated to assess the validity of analysing hair samples 
for the presence of AF in victims of drowning. Ten amfetamine positive hair samples were 
submerged in fresh and sea water for different periods of time. The drug concentrations in 
the samples were monitored over a period of 8 weeks. Hair samples were analysed using 
the validated method. The results showed a significant decrease of amfetamine in hair 
with the time submerged in sea water. Fresh water had a much less significant effect over 
the study period. 
The validated method was successfully applied to 16 case samples obtained from living 
volunteers with a known history of fenethylline (AF precursor) abuse and 6 post-mortern 
case samples where amfetamines had been detected in the post-mortern blood. 
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1 Introduction 
1.1 Overview of drug use 
The problem of drug use and abuse has existed for a very long time. Over the last 200 
years, most of the countries in the world have suffered from this problem. Differences 
vary from country to country but the epidemic has risen with time. There is no doubt that 
there are serious negative effects of drug abuse on the health and security of the social 
structure of all nations. It estimated that 30,000 premature deaths per year in the United 
States are attributed to illegal drugs and the numbers are growing continually [2]. The 
official statistics of the British Crime Survey (BCS) in 2004/5 indicated that 34.5% 
(approximately 11 million people) of 16 to 59 year olds in England and Wales had used at 
least one illicit drug in their lifetime. It was reported that the extent of cannabis use 
decreased between 2003/04 and 2004/05, and amfetamines use decreased between 1998 
and 2004/05 in England and Wales among this age group (16 to 59 year old) [3]. 
1.1.1 Drug of Abuse 
There are various definitions of a "drug of abuse" Most of them focus mainly on the use of 
a substance for some purpose other than that intended. For example a drug which is used 
therapeutically but can cause harmful effects when taken irresponsibly. Illicit drugs are 
restricted by the law, with possession or supply carrying legal penalties. As such they are 
prohibited by govemments [4]. 
1.1.2 The Misuse of Drugs Act 1971 
The Misuse of Drugs Act 1971 is an Act in the United Kingdom and its aim is to control 
the possession and supply of numerous listed drugs and drug-like substances whether they 
be illegal drugs or prescription medications and to enable international co-operation 
against illegal drug trafficking. There are different penalties for possession and supply of 
controlled drugs under the Misuse of Drugs Act depending on the nature of the offence. 
These are summarised in Table I. I. This Act allows regulation in the use of some 
controlled drugs by various professional people in different fields such as doctors [5]. 
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Table 1.1 Penalties under the Misuse of Drugs Act [6] 
Class Drugs 
A Ecstasy, LSD, Heroin, Cocaine, Crack, 
Magic Mushrooms, Amfetarnines (if 
prepared for injection) 
BI Amfetamines, Methylphenidate (Ritalin), 
Pholcodine 
C Cannabis, Tranquillisers, some Painkillers, 
Gamma hydroxybutyrate (GHB), Ketamine 
1.1.3 Control Drugs Classification 
Penalties 
Possession: Maxiinum of 7 years 
in prison and/or unlimited fine 
Supply: Up to life in prison 
and/or unlimited fine 
Possession: Maximum of 5 years 
in prison and/or unlimited fine 
Supply: Maximum of 14 years in 
prison and/or unlimited fine 
Possession: Maximum of 2 years 
I in prison and/or unlimited fine 
Supply: Maximum of 14 years 
and/or unlimited fine 
In the United Kingdom, illegal drugs are classified into three classes A, B and C depending 
on their potential for abuse toxicity. These regulations are continually amended whether 
adding new drugs, upgrading or downgrading these drugs in each class [5]. Class A has 
the most harmful drugs and highest penalties and Class C drugs are the least harmful and 
have the lowest penalties. The regulations of controlled drugs for possession, supply, 
production and importation or exportation were made under this Act to meet the medical or 
scientific needs. These are categorised as follows: 
Schedule 1: Drugs which are the most stringently controlled, not for medical use and 
usually for research purposes for example cannabis, coca leaf, ecstasy, LSD and raw 
opium. 
Schedules 2 and 3: Drugs which are illegal to possess without prescription. Schedule 2 
drugs include arnfetamines, cocaine, dihydrocodeine, diconal, heroin, methadone, 
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morphine, opium in medicinal form, pethidine and ritalin. Schedule 3 includes 
barbiturates, rohypnol and temazeparn tranquillisers. 
Schedule 4: Part 1. Drugs which are illegal to possess without a prescription, for example, 
most minor tranquillisers. Part 2. Drugs which are legal to possess in their medicinal form 
without a prescription, but it is illegal to supply them to other people, for example, 
anabolic steroids. 
Schedule 5: Drugs which are allowed to be sold over-the-counter at a phannacy without a 
prescription, and may be bought by anyone with impunity, for example, cough medicines, 
anti-diarrhoea agents and mild painkillers [7]. 
1.2 Forensic Toxicology 
1.2.1 Introduction 
Toxicology is the comprehensive study of poisons and drugs, concerned with their effects 
on living organisms and dealing with the diagnosis of poisoned people. 
Forensic toxicology is the study of the effects of drugs and poisons on human beings in the 
context of the law. The use of toxicological investigations for the purpose of medico-legal 
enquiries for living and deceased people depends on the country [8,9]. 
A toxicologist deals with different biological samples such as urine, blood, hair, sweat, 
saliva, other body fluids and organs such as liver, kidney and brain, to investigate the 
presence of a toxic substancc[9]. Urine is the most common specimen used for drug 
testing [10]. 
The main objective of toxicological analysis is to prove or exclude the presence of 
undetermined toxic substances in biological matrices and accurately identify them. The 
analyst must be capable of identifying and quantifying these substances within a specified 
time period [I I]. 
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1.2.2 Systematic Toxicological Analysis (STA) 
Systematic Toxicological Analysis (STA), is a process which involves the identification 
and quantitation of unknown substances [11]. To analyse drugs in conventional biological 
matrices, Systematic Toxicological Analysis involves three stages, pre-treatment and 
extraction, detection and identification. 
1.2.2.1 Pre-treatment and Extraction 
The biological samples undergo pre-treatment in STA and this pre-treatment depends on 
the type of the sample, for instance whether they are biological fluids or tissue samples. 
Buffer solutions are widely used for dilution of plasma and serum [12]. Hydrolysis and 
protein removal are used in the preparation of biological samples. Pre-treatment is often 
carried out by enzyme preparations like fl-glucuronidase or strong acid and basic agents 
which are necessary to split conjugated metabolites. Enzyme pre-treatment is preferable 
because strong acid and base can cause substances to decompose. Protein removal can 
also cause low recoveries due to drug molecules being bound to the precipitated protein. 
An extraction method is required to concentrate drugs of interest and to remove any matrix 
compounds. This is done using a variety of techniques such as Liquid-Liquid Extraction 
(LLE) and Solid-Phase Extraction (SPE). In order to achieve optimum results extraction 
procedures should have high recoveries, be capable of separately extracting a wide variety 
of target analytes (acidic, neutral and basic), have clean extracts and be reproducible and 
rapid. SPE can be used for the extraction of single drugs or groups of related drugs, and 
has become the most popular extraction technique [I I]. 
1.2.2.2 Derivatisation Methods 
Analysis of drugs by GC or GC-MS may require derivatisation to make substances 
appropriate for analysis. It is essential for the analysis of polar and thermally labile 
compounds to make them volatile and thermally stable. The main purpose of the 
derivatisation step is to improve chromatographic properties such as better peak shapes and 
increased resolution from related compounds. This is achieved by increasing the volatility 
and stability, while decreasing the polarity of the compounds. Another benefit is often the 
formation of ions at higher mass/charge ratios, giving more diagnostic mass spectra. 
Greater sensitivity can be obtained by introducing groups of high electron affinity (such as 
halogen atoms), these increase the ionisation efficiency. The optimum derivatisation 
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reaction should be simple, rapid and complete, and produce a stable, single derivative with 
good reproducibility. The derivatisation of different functional groups on analytes can 
include hydroxyl groups, ketones, carboxylic acids and amines. The three most common 
derivatisation methods are silylation, acylation and alkylation. 
1.2.2.2.1 Silylation 
Silylation occurs when an active proton in -OH, -SH or -NH groups is displaced with an 
alkylsilyl group from the silylation reagent. Some protic functional groups on the 
compound are converted to either silyl ethers or esters. The ability of various functional 
groups to form silyl derivatives was found to be as follows, alcohols > phenols > 
carboxylic acids > amines > amides. Trimethylsilylation is the most commonly used 
procedure for silylation. There are a variety of trimethylsilylating reagents available such 
as trimethylhalosilanes, TMS-amines, TMS-esters and TMS-amides, which are varied in 
their properties, for instance: volatility, reactivity and selectivity. MSTFA is the most 
volatile TMS-amide used to form TMS derivatives of alcohols and phenols. 
Trimethylsilylimidazole (TMSIm) is another silylation reagent used for hydroxyl and 
carboxyl groups and tert-Butyldimethylsiyl (TBDMS) derivatives are used to increase 
hydrolytic stability and to give useful mass spectrometric fragmentation. All silylation 
reagents and derivatives are sensitive to moisture [13]. This is the general silylation 
reaction in the formation of trialkylsilyl derivatives [14]: 
R3Si-X +R'-H - R3Si- R'+ HX 
1.2.2.2.2 Acylation 
Acylation occurs by introducing an acyl group on to a molecule containing a reactive 
hydrogen. There are many functional groups that may be acylated to produce derivatives 
such as alcohols, amines, amides, thiols, phenols, enols, sulfonamides. The acylation 
reactions can be carried out by acyl halides, acid anhydrides or reactive acyl derivatives. 
acyl halides are highly reactive. Perfluoroacyl derivatives such as trifluoroacetyl (TFA), 
pentafluoroproionyl (PFP) and heptafluorobutyryl (HFB) are the most commonly used. 
These perfluoroacyl derivatives lead to an increase in the abundance of high m/z ions [13]. 
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The general acylation reaction is as follows [141: 
00 
11 11 
R-C-X + RT-H 3m R-C-RY' + HX 
1.2.2.2.3 Alkylation 
Alkylation is another commonly used derivatisation method, which replaces an active 
hydrogen as in carboxylic acids, alcohols, thiols and amines with an alkyl or an aryl group. 
Alkyl halides, iodides (methyl, ethyl, propyl, isopropyl) or benzyl and most substituted 
benzyl bromides are the most common reagents used to obtain alkyl derivatives [13]. One 
type of alkylation reaction is as follows [ 141: 
R-COOH + R'X - R-COOR'+ HX 
1.2.2.3 Detection 
After biological sample preparation, the analysis of drugs in biological matrices usually 
involves several analytical techniques for qualitative or quantitative analysis of drugs. 
There are several types of commercial techniques available. For screening purposes 
immunoassays (IA) and occasionally thin-layer chromatography (TLC) can be used. For 
confirmation purposes gas chromatography (GQ, with a detector such as flame ionisation 
detection (FID), nitrogen-phosphorous detection (NPD), electron capture detection (ECD) 
and mass spectrometry (MS) can be used. Also high-performance liquid chromatography 
(HPLQ, with detectors such as ultraviolet spectrometry (UV), diode array detection 
(DAD), electrochemical detection (ECD) and mass spectrometry (MS) can be used for 
confirmation [15]. 
GC-MS is the technique of choice in forensic toxicology and can be used for STA [111. 
The major advantages are good sensitivity and specificity. 
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1.2.2.4 Identification 
Commonly encountered drugs have well defined mass spectra which are reproducible 
between instruments. Identification of unknown substances is not easy due to the large 
number of possibilities. Comprehensive libraries do exist but need to be updated regularly 
to cover as many drugs as possible. 
1.2.3 Solid Phase Extraction 
1.2.3.1 Introduction 
SPE is a physical extraction process for rapid sample preparation in which a solid 
(stationary phase) is used to selectively extract, concentrate, and purify the analyte of 
interest in the biological matrix prior to chromatographic analysis. 
SPE was introduced commercially in 1970 as a technique for urine sample preparation and 
in 1979 the small size columns of modem SPE was first used. Its applications included 
pharmaceutical, industrial, environmental, clinical, and forensic fields for the extraction of 
substances. In the last few years, there has been a trend toward replacing the classical LLE 
by SPE due to its potential advantages, there are visible practical advantages of SPE 
compared to LLE which could be useful in drug extraction, including the following: 
o high specificity 
* high analyte recoveries 
e cleaner extracts and enhanced removal of interferences and particulates, lead to less 
equipment contamination 
9 elimination of emulsions 
better reproducibility of results 
reduced solvent consumption, as well as reduction in hazardous and environmental 
wastes 
ease of use and the SPE extraction can be automated 
enhanced analytical sensitivity and reduced LOD and LOQ 
* lower sample quantities and shorter sample extraction times [12,16,17] 
As a result of the difficulty in extracting a wide range of drugs by a single mode column, 
the mixed mode bonded silica SPE columns such as Bond Elut CertifyTm and 
CleanScreenTm can be used. These columns contain both hydrophobic and cation 
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exchange functional groups properties, which allow the extraction of a broad range of 
drugs including acidic, neutral and basic drugs by selectively eluting with various clution 
solvents. The majority of reviews have focused on the use of SPE to extract individual 
drugs or classes of drugs [12]. 
1.2.3.2 Principles of Solid Phase Extraction 
SPE sorbent (base support) plays a major role in SPE extraction efficiency and separation 
quality, there are various sorbent materials in use like silica or bonded silica, alumina and 
polymers, but bonded silica is the most popular sorbent used [12,16]. 
The functional group bonded to the silica determines the interaction mechanism 
(extraction) between the functional groups of the sorbent with the analyte of interest. The 
common interaction mechanisms between sorbent and analytes are as follows: 
1.2.3.2.1 Non-polar Interactions (Reversedphase) 
Non-polar interactions are carried out between the hydrocarbon chains of hydrophobic or 
polar organic analytes and the sorbent. These interactions are caused by low energy Van 
der Waals (dispersion forces). Saturated hydrocarbon chains such as C18 and C8, or 
aromatic rings such as phenyl (PH) are usually used in non polar sorbents. These sorbents 
have the ability to retain a wide range of organic compounds, due to the non specificity of 
the interaction [12,16]. 
1.2.3.2.2 Polar Interactions (Normalphase) 
Polar interactions are used to extract polar analytes from non-polar organic solvents. The 
analytes are retained on the sorbent due to hydrogen bonding, dipole-dipole and 7r-7r 
interactions between polar analytes and the polar sorbent. A high degree of specificity is 
obtained by optimizing the polarity of the conditioning solvent and the elution solvent [12, 
16]. 
1.2.3.2.3 Ion Exchange Interactions 
Ion exchange interactions take place between charged sorbents and the analytes from low 
ionic strength aqueous or organic samples with the opposite charges, for example a 
negatively charged sorbent (cation exchangers) will retain positive charged analytes and in 
Diagnostic Use ofHair Analysisfor the Detection qfMisuse ofAmfelamines and Cannabinoids 
Chapter One: Introduction Page 23 
contrast a positively charged sorbent (anion exchangers) will retain negatively charged 
analytes. This mechanism has a high degree of specificity, therefore, the contamination in 
the matrix is easy to wash out [ 12,16]. 
1.2.3.3 Solid Phase Extraction steps 
1.2.3.3.1 Column Preconditioning 
To prepare the column sorbent to receive and interact with analytes, the column sorbent 
needs suitable conditioning prior to the sample application in order to improve 
reproducibility and recovery. This is done using polar solvents to activate and open up the 
coiled hydrophobic portion of the sorbent. The sorbent conditioning can vary depending 
on the type of analyte [12,18]. 
1.2.3.3.2 Sample Application 
Sample application follows the column precondition. A low flow rate is required to allow 
the drugs of interest to have adequate time to interact with the sorbent, consequently more 
drugs are retained on the column and selectively eluted, thereby increasing recovery [12]. 
1.2.3.3.3 Column Wash 
In order to remove endogenous components rather than the drugs of interest which have 
bound to the sorbent during sample application, the column is washed. An appropriate 
wash solvent has to be chosen very carefully in order to avoid loss of the target analyte 
during the wash process. At this step, the pH of the column is adjusted as some of the 
drugs are dependant on the pH for their elution [12]. 
1.2.3.3.4 Column Drying 
Residual water should be removed from the SPE column prior to the elution of the drugs of 
interest and prior to analysis by washing with a suitable organic solvent or drying the 
sorbent with air under vacuum. The presence of water prevents the optimal elution of the 
drugs as a result of the immiscibility of the elution solvent with water, on the other hand, 
the presence of water may react with the stationary phase of the column, consequently 
causing damage to the GC column [ 12,17]. 
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1.2.3.3.5 Elution ofRelevant Drugs 
The final step in extraction of the drugs of interest should be elution with the appropriate 
solvents. These have to be strong enough to elute the drugs of interest completely with a 
small eluent volume and should be selective to avoid elution of interfering compounds 
[12]. 
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2 Hair Analysis 
2.1 Introduction 
Hair analysis is useful for detecting and monitoring past drug use over a period of weeks to 
several months depending on the length of the hair sample and on the stability of the drug 
in the hair specimen. It has been shown to be useful in the detection of chronic drug abuse 
in forensic and clinical applications and has been used for the purpose of employment 
screening, monitoring compliance for drug treatment programs, in cases involving criminal 
responsibility, detection of drug use in utero and the passive exposure of the fetus, in cases 
of driving license suspension and in the investigation of abstinence for chronic drug 
abusers. Hair analysis can be used as a complementary technique to urine and blood 
analysis which show relatively recent usage. The combined information from these types 
of sample and hair will provide information regarding acute and chronic use [ 19]. 
The exact time of drug ingestion cannot be determined from hair analysis results. The 
estimation of the ingestion time is only possible in intervals of months not in weeks, days 
or hours. This is because there are many varying factors involved in the incorporation of 
drugs into hair [20]. These are discussed later on in section 2.5. The time of drug 
consumption can be approximated in months by knowing the rate of hair growth in an 
individual and the location of the drug along the hair shaft [21]. 
The first poisonous substance to be determined in hair was arsenic in 1857 by Casper. It 
was found in the hair of a body exhumed eleven years after burial [22]. In 1954, the first 
organic drug (AF) was detected in guinea-pig hair [23]. Due to the capability of atomic 
absorption spectroscopy to detect low concentrations of elements (nanograms per 
milligram), hair analysis was used in 1960s and 1970s to detect toxic heavy metals, such as 
lead or mercury in hair [24]. 
The first report of the detection of opiates (heroin/morphine) in hair was reported in 1979 
using a radioimmunological method. This publication was the first method which dealt 
with drugs of abuse in human hair and it led to many further investigations in this area 
[22]. The first paper to confirm radioimmunological results with a chromatographic 
method was printed in 1980 [25]. The availability of more sensitive and selective 
analytical methods allowed for the detection of low levels of drugs which were 
incorporated into the hair in the picogram per milligram range. 
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The role of hair drug testing in toxicological applications has been widely discussed by 
different scientific communities such as the Society of Forensic Toxicologists (SOFT) and 
the Society of Hair Testing (SOHT) [26]. These scientific conferences are important to 
address controversial issues surrounding hair analysis. SOHT in 2004 set out 
recommendations for testing of drugs in hair. A consensus was reached to include points 
on sampling, shipping and storage, decontamination, hair disintegration, the screening test, 
criteria for mass spectrometric analysis, specific drug classes (opiates, cocaine, 
amfetamines, cannabinoids), internal quality control, external quality control [27]. These 
provide guidelines for laboratories carrying out hair analysis for drugs. 
The potential advantages of hair analysis over other conventional or unconventional 
biological specimens are: 
" collection of hair specimens is easy. 
" sampling is less intrusive. It is less embarrassing than urine collection which 
requires close supervision. 
" adulteration is difficult. 
*a second sample can be obtained if there is any doubt about the integrity of the 
sample. 
long time stability of hair specimens at room temperature. This means they can be 
stored and transported indefinitely without refrigeration and quick analysis is not 
required. 
it has a wider window of detection than blood or urine. The window of detection 
will depend on the length of the hair. 
* periods of abstention can be identified. 
parent drugs and metabolites are incorporated into hair. Urine and blood samples 
often only have the metabolites present [28-3 1 ]. 
2.2 The Anatomy and Physiology of Hair 
2.2.1 Introduction 
The interpretation of drug concentration results in hair is complex. To avoid the 
misinterpretation of results, an understanding of hair biology such as the anatomy, 
physiology, biochemistry and growth cycle is necessary to provide the correct scientific 
interpretation of the drug results in the hair. 
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2.2.2 Structure of hair 
Hair is a cylindrical shaft which grows from a small sac called the hair follicle. Hair varies 
morphologically from individual to individual, within the same individual as well as within 
a single region within an individual. Hair emerges from the skin either in single strands or 
in groups [32]. Hair consists of three layers of cells as shown in Figure 2.1. 
The cuticle is the outermost layer of the hair shaft, which plays a role in anchoring the hair 
shaft in the hair follicle and acts to protect the interior layers of the hair shaft. The cuticle 
consists of a single layer of elongated, overlapping cells and is free of pigment. The 
thickness and length of each cuticle cell is around 0.5 to 1.0 ýLrn and 45 gm, respectively. 
Exposure of the hair to harmful substances and environments such as chemical, heat, light 
or mechanical treatment can damage or destroy the cuticle. The cuticle acts as a strong 
barrier against the loss of drug integrity. When the cuticle is damaged drugs may be 
removed more easily from the hair [ 19,3 3,3 4]. 
The cortex is the middle layer and the bulk of the hair shaft. It contains lengths of 
keratinised cells and also melanin granules which are the principle pigment in hair, eyes 
and skin. Hair colour depends on the quantity, distribution and type of pigment in hair. In 
the cortex there are small air spaces between the cortex cells called fusi which are filled 
with fluid and replaced by air as the hair grows and dries out [33]. 
The medulla is the innermost layer of the hair shaft. This layer exists in human hair and 
can be continuous, discontinuous or absent. The medulla layer contains many keratinized 
cells. Intra and intercellular air spaces are also found in this layer as well [32,33]. 
Melanin granules may also be present in the medulla. 
There are two types of melanin in human hair, ears and in certain brain structures in man. 
They play an essential role in the protection of internal tissues against UV radiation [35]. 
Their structures can be very simple or very complex [36] and some of these are still not 
fully understood [37]. In hair they are attached to the protein matrix [38]. 
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Figure 2.1 Cross-section of a hair shaft [39] 
2.2.3 Hair Composition 
Human hair contains proteins called keratin that are bound together tightly to form long 
fibres, producing a stable structure. The proteins are rich in sulphur. Proteins, water, 
lipids and minerals represent approximately 65 to 95%, 15 to 35%, 1 to 9% and 0.25 to 
0.95% of hair content respectively. These percentages depend on the moisture in the hair. 
Trace elements and heavy metals are also present. 
2.2.4 The Hair Follicle 
The hair follicle is a small sac that surrounds the hair root. It is found 3 to 4 mm below the 
skin's surface and is embedded in the epidermal epithelium of the skin. 
Sebaceous and apocrine glands surround the hair follicle. Their ducts secrete into the 
follicle. In addition to these glands, the eccrine sweat gland also surrounds the hair follicle 
in axillary and pubic areas. Its duct does not secrete into the follicle but near to the exit of 
the hair follicles, onto the surface of the skin. The secretion of these glands may be a 
source of trace elements and drugs in hair. The sebaceous gland and eccrine sweat gland 
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are located and distributed near the surface of the body. The apocrine gland is located in 
the axilla, the external auditory meatus, the eyelids and perineal region. 
There are three regions in the hair follicle. The first region is the innermost region (lower 
segment) in and around the bulb. In this region the biological synthesis of hair cells is 
carried out. The second region (middle segment) is the keratogenous region. This region 
extends from above the bulb. Keratinization, hair hardening and solidification take place 
in this region and the final region (upper segment) is the permanent hair region. In this 
region dehydrated cornified cells make up the hair shaft. Figure 2.2 shows a cross section 
of the skin surrounding a hair follicle [33]. 
Hair shaft 
Sebaceous 
(oil) gland 
Follide 
R 00t 
Blood vessels 
Figure 2.2 A cross section of the skin surrounding a hair follicle [40] 
Arrector 
pili muscle 
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2.2.5 The Hair Growth Cycle 
Hair grows in a cycle which consists of three phases: 
The first phase is the anagen phase. It is known as the growth phase due to the metabolic 
activity of the matrix cells increasing and hair being produced in the follicle. Hair cells are 
produced and the keratinzation process begins. This phase lasts around 2 to 3 years and its 
growth rate is dependent on the anatomical region. The nutrients and extraneous materials 
such as trace metals and drugs supplied by capillary blood are incorporated into the hair 
shaft at this phase. 
The second phase is the catagen phase. It is a transition period of about 4 to 6 weeks, 
between active growth and a resting phase. This phase produces a fully keratinized root 
which is club end formed and separate from the bulb of the hair follicle, the club hair 
becomes a white node, then cell division stops and the follicle becomes shorter. 
The third phase is the telogen phase. This phase is characterized as the club and is 
completely separated from the bulb becoming close to the scalp surface. No hair grows 
and it is easily removed by pulling. It lasts a period of between 2 to 3 months depending 
on the hair type and age. The anagen phase and telogen phase represent approximately 
85% and 10 to 15% of hair growth on the scalp of adult respectively, in the catagen phase 
some hair is passed. A new hair shaft begins to grow, while the old hair is forced out [19, 
33,41]. Figure 2.3 shows the hair growth cycle phases. 
Anagen phase Catagen phase Telogen phase New anagen phase 
Figure 2.3 Hair growth cycle phases [34] 
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2.2.6 Rate of hair growth 
Hair growth rate varies between individuals and also within an individual. Thus, the 
precise determination of hair growth rate is difficult. The average growth rate of human 
head hair is I cm. /month. In general, hair growth rate depends on a number of factors such 
as hair type and anatomical location. For example, scalp hair grows much faster than hair 
in the pubic or axillary regions which in turn grows faster than beard hair. Many others 
factors affect the hair growth rate. These include race, sex and age. Scalp hair in women 
tends to grow faster than in men and there is a decrease of hair growth rate as adults age. 
Therefore, these factors have to be taken into account when interpreting hair drug results 
[33]. The time taken for the drug to appear in the hair shaft at the skin's surface for a 
medium growth rate of 1 cm/month was estimated to be between 9 and 14 days. It was 
reported in another study that codeine was detected between 15 and 21 days after a 120 mg 
dose for a segment >1 cm from the skin surface [34]. 
2.2.7 Types of Hair 
There are three basic hair types on the human body. These are vellus, terminal and 
intermediate and each has their own individual properties. These differ in length, texture, 
colour, diameter and shape. Vellus hair is fine, short, non-pigmented and has a small 
cross-sectional area. This type of hair is found on the eyelids, the forehead and on the bald 
scalp. Terminal hair is coarse, long, pigmented hair with a large cross-sectional area found 
in scalp, beard, eyebrow, eyelash, armpit and pubic areas. Intermediate hair is of 
intermediate length and shaft size and is found on the arms and legs of adults. 
There are three kinds of follicles which produce different hair types on the human body. 
Intermediate hair is produced from nonsexual hair follicles which are not influenced by 
hormones and do not change after puberty. While ambosexual hair follicles are influenced 
by hormones and therefore will change during puberty. These affect hair in the axilla, 
pubic regions and on the temple area of the scalp. Male hair follicles exist in males and 
affect hair in beard area, cars, nose, chest, abdomen and top of the head [33]. 
2.3 Hair sample collection 
The posterior vertex region, at the back of the head, is the preferred site of collection of a 
hair sample rather than other samples such as beard, axillary, pubic hair and other areas of 
the head. This is because this region is characterized with a high percentage of follicles in 
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the anagen phase, which are a uniform distance from the scalp. This is especially 
important if sectional analysis is required. The highest and the fastest growth rate is also 
found at the vertex region in the scalp, up to 3.4 cm/month. Beard hair has the slowest 
growth rate (approximately 0.8 cm/month) and pubic hair is also slower than scalp hair 
(0.9 cm/month). In this area the effect of age and sex on the incorporation of drugs have 
less influence. Pubic hair and axilliary hair is used as an alternative to scalp hair when it is 
not available. However the problem of possible exposure to contamination by urine and 
sweat should be recognised [ 19,33,34,41 ]. 
The different concentrations of drugs in the pubic, axillary and scalp regions has been 
reported in various studies and these differences are attributed to a number factors such as 
presence of apocrine glands, blood supply, different telogen/anagen ratios and hair growth 
rate [24]. 
2.4 Drug incorporation into hair 
In order to interpret hair analysis results accurately, the incorporation of drugs into hair has 
to be considered. At present, the exact understanding of the incorporation of drugs into 
hair is unknown. The transfer of drugs from the body to hair is suggested and carried out 
by various proposed mechanisms at different times of hair growth cycle. 
The first mechanism is simple passive diffusion, in which drugs transfer from the blood 
into the growing hair cells and bind tightly with the interior of hair shaft during 
keratogenesis (during fonnation). 
The second mechanism suggested is transfer from sweat, sebaceous and apocrine gland 
secretions (after formation). 
The third proposed method is from the external environment such as smoke, powder and 
absorption by skin after formation and when the hair has emerged from the skin. 
Incorporation of drugs into hair from tissues surrounding the hair follicle and deep 
compartments in skin which can accumulate lipophilic drugs in the epidermis and the 
hypodermis layers cannot be excluded. Figure 2.4 shows the different proposed 
mechanisms of drug incorporation during different phases [42,43]. 
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It was reported that codeine was detected in the hair root 30 minutes after administration 
and detected in distal scalp hair for up to 10 weeks after a single dose of the drug. The 
study was only carried out for a period of 10 weeks [2 1 ]. 
It has been reported that methamfetamine (MA), methylendioxymethainfetamine (MDMA) 
and phencyclidine were found in rat hair root within 5 minutes of administration. Thus, 
the hair root can be used as an indicator of recent drug use. It has been reported that the 
concentration of drug in hair is dependent on the amount of drug incorporated into hair and 
retained in hair, where some of the incorporated drug is redistributed outside the hair shaft 
(44]. 
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Figure 2.4 Diagram showing the possible mechanisms for drugs incorporation into the hair 
[42] 
2.5 Factors affecting drug incorporation into hair 
Lipophilicity, melanin affinity and pKa are important factors that may influence the 
incorporation of drugs into hair. For example, basic drugs are readily incorporated into 
hair, while acidic drugs exhibit a weak incorporation into hair [45]. Another factor which 
has been suggested to influence the incorporation of drugs into hair is colour. For 
example, the drug concentrations tend to be higher in hair that contains pigment than hair 
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that does not. It has been reported that cocaine was incorporated in the hair of African 
American females with black hair at concentrations higher than in the hair of Caucasian 
males or females with coloured hair. This has been reported as racial bias. Other possible 
factors are gender differences, the structure of the hair such as fine hair versus coarse hair 
[21,46,47] and cosmetic treatment (colouring , 
bleaching, penning) [48]. 
In addition, pKa plays a major effect in drug transport and incorporation of drugs into hair. 
For example the difference in pH between plasma (7.4) and the matrices cells like 
melanocytes (3-5) leads to the accumulation of basic drugs in the matrices cells, due to a 
negative concentration gradient of penetrable non protonated basic drugs from plasma to 
the cytosol of the matrices cells. In contrast, acidic drugs like A? - tetrahydrocannbinol 
carboxylic acid will be transported in the opposite direction. This may be part of the 
reason why its concentration is low in hair matrices. The binding of drug with melanin is 
affected by pH as well [34]. 
2.6 Hair Decontamination 
The contamination of hair from external sources is a problem in hair analysis for the 
detection of drugs [43,49-52]. Decontamination procedures are used to remove non-drug 
contaminants such as dirt and oils from hair but are also necessary to eliminate external 
contamination prior to hair analysis to avoid false hair positive results from passive 
contamination for example from being in the environment of drug smoke or from handling 
drugs and then hair. 
There is no set standard procedure to remove contamination from hair. Currently, different 
solutions such as water, Tween, SDS, other detergents, phosphate buffer, methanol, 
ethanol, acetone, dichloromethane, isopropanol are used in various combinations to 
decontaminate the hair. However, it is difficult to fully validate decontamination 
procedures. This is because it is not clear if all of the contaminant is being completely 
removed or if drug which has been incorporated through use is also being removed. It has 
been reported that the decontamination of hair depends on the hair type, where certain 
types are more resistant than others in removing environmental contamination. For 
example thick black hair was demonstrated to be more resistant to decontamination than 
other hair types. The basic concept of decontamination procedures is to remove potential 
drugs which are loosely bound to the surface. However, it has been shown that drugs from 
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passive contamination is not only on the surface of the hair but also present in the interior 
of the hair [50]. 
One study showed that decontamination procedures could not remove all external 
contamination of opiates (heroin, 6-MAM, morphine, acetylcodeine and codeine) by using 
5 ml of dichloromethane for 5 min at room temperature three times. 5 mg of a powdered 
mixture of heroin hydrochloride and acetylcodeine (10: 1 w/w) was applied to subjects' 
hands for 5 minutes and this was wiped onto the hair. This method of contamination may 
not be realistic. The authors attempted to use cut-off values and metabolite-to-drug ratios 
to evaluate sample contamination but concluded these methods were not practical. They 
suggest that the reporting of a positive hair result alone is not acceptable without other 
evidence for example further toxicology tests such as urinalysis or clinical data [43]. 
In contrast, another paper [53] reported an extensive decontamination procedure to remove 
external contamination from hair. Various experimental models such as soaking and 
coating with cocaine, morphine and 6-MAM, PCP and methamfetamine drugs were used. 
Attempts to identify the contamination of the hair sample were carried out by subtracting 
the multiplied value of the last washed fraction from the amount of drug found in the hair 
sample following digestion. When the results were less than the cutoff for the parent drugs 
the contamination was reported to be from external contamination and the result reported 
as negative. If the result was higher than the cutoff for the parent drugs this was reported 
to indicate active drug use and the result reported as positive. 
The effect was evaluated for four different wash procedures on the quantitative 
measurement of cocaine and its metabolites from rat hair. The cocaine was administered 
by intraperitoneal injection. All four methods showed different drug concentrations in hair 
compared with unwashed hair. This showed that all four washes have the potential to 
remove systemic drug exposure from hair. This study proved that wash procedures are 
capable of removing environmental contamination and incorporated drug whether from 
active or passive use [54]. 
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3 Arnfetarnines and Cannabinoids 
3.1 Amfetamines 
3.1.1 Introduction 
0-phenethylamine derivatives such as amfetamine (AF), methamfetamine 
(MA) and 'designer drugs' such as methylenedioxy derivatives of 
amfetamine including 3,4-Methylenedioxyarnfetamine (MDA), 3,4- 
Methylenedioxymethamfetamine (MDMA), 3,4-Methylenedioxyethyl- 
amfetamine (MDEA), N-methylbenzodioxazolbutanamine (MBDB) and its methoxy 
derivatives for instance para-methoxyarnfetainine (PMA), para-methoxymethamfetarnine 
(PMMA) and 4-methylthioarnfetamine (4-MTA) are powerful stimulants of the central 
nervous system [55]. AF and related compounds are listed in Classes A and B of the 
Misuse of Drugs Act 1971 [3]. 
The drugs are widely abused, primarily by young people, in different areas of the world. It 
is reported that AF and MDMA are the most common drugs used from this class of 
compounds and are used either alone or in combination with other illicit drugs [56]. 
Consequently, these drugs are of interest to forensic and clinical toxicologists and to sports 
scientists. Traditionally, these drugs would be detected in blood or urine specimens. 
However, with concerns relating to the human rights of individuals, privacy and dignity, 
less conventional biological specimens such as oral fluid, hair, sweat and nails are 
becoming more frequently used for drug screening, particularly in the workplace. 
According to the European Monitoring Centre for Drugs and Drug Addiction (EMCDDA) 
the abuse of AF and related compounds comes second to cannabis misuse in Europe [571. 
3.1.1.1 Amfetamine 
AF is a central nervous system stimulant. It is available as amfetamine phosphate and 
amfetamine sulphate and is ingested as a racemic mixture [58]. It was first synthesised in 
1887 and used during World War 11 to prevent fatigue and maintain alertness. It has been 
manufactured commercially since 1932. Its misuse was reported to have spread to Japan, 
Europe, Canada and the US in the 1960s. It can be abused by oral, nasal or intravenous 
routes [55,59]. The clinical use of AF was limited to the treatment of narcolepsy in adults 
and attention deficient disorder with hyperactivity (ADHD) in children. Also it has been 
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used in decongestant preparations and as an appetite suppressant [60]. The popularity of 
AF competes with cocaine on the street as a result of it being cheaper and giving a similar 
effect. For example, 5-10 milligrams of dextroarnfetamine is sufficient to ward off fatigue 
and produce mental and physical effects such as euphoria. Consequently, it is a popular 
illicit stimulant among students, truck drivers, night workers and athletes. Side effects of 
the drug include dryness of the mouth, sweating and hypertension [6 1 ]. 
3.1.1.2 Methamfetamine 
MA is a strong central nervous system stimulant and is available as metharnfetamine 
hydrochloride [58]. MA was synthesized in the early 1900s for clinical use. It was highly 
abused and caused problems in different countries such as the US, Mexico, South America, 
the Middle East, Asia and Australia. It is abused through smoking, insufflations, injection 
and oral ingestion. Clinically, its use is limited to weight loss programs and for the 
treatment of narcolepsy in adults and to treat attention deficit disorder in children and 
exogenous obesity [62-64]. It was reported that 4% of the US population has tried this 
drug during 2000 [65]. 
3.1.1.3 Methylenedioxy Derivatives 
MDA, MDMA and MDEA are methylenedioxy derivatives of amfetarnines. The 
derivatives were synthesised to circumvent the then legal controls on amfetamines. They 
are abused for similar reasons and have similar phan-nacological actions to the 
arnfetamines (see section 3.1.1.1). Also, they were found to have some hallucinogenic 
properties. Although there were claims that MDMA could be used diagnostically by 
psychiatrists, the drugs have no significant therapeutic use. They are available as 
methylenedioxyamfetamine hydrochloride, methylenedioxymethamfetamine hydrochloride 
and methylenedioxyethylamfetainine [58,66]. Methylenedioxy derivatives of amfetamine 
or methamfetamine are abused to enhance understanding and empathy [67). They became 
the most popular recreational drugs in the mid-1980s [55]. Within recent years, they have 
become the second most popular abused drugs in Europe and North America especially at 
dance clubs as "rave" drugs [68]. 
MDMA and MDA were first synthesised in 1914 and 1910, patented in 1914 and 1940 
respectively. Since 1986, clandestine laboratories started to synthesise derivatives of 
MDMA and MDA [69]. Methylenedioxy derivatives of anifetamines are mostly consumed 
orally and originally were synthesised for medical use [70,71]. Their popularity was due 
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to producing effects such as euphoria, enhanced energy, a desire to socialize and their 
reputation of being safe. Other studies, however, indicated some harmful effects to 
humans such as hepatotoxicity and neurotoxicity [72]. Following the use of the 
methylenedioxy derivatives of arnfetamine the abuser may experience drowsiness, muscle 
aches, general fatigue, depression lasting 1-2 days and may have difficulty in 
concentrating [68]. 
It has been reported that the development of new designer drugs has increased during the 
last few years. Approximately 200 different derivatives have been described. A few of 
them are known to be used in Europe where the methylenedioxy derivatives of amfetamine 
and methamfetamine are the largest designer drugs group abused [73]. 
3.1.2 Physico - Chemical Properties of Amfetamines 
Chemically, these compounds are derivatives of 9-phenyl-isopropylamine. AF contains a 
primary amine and MA has a substituted amine. Methylenedioxy derivatives are ring- 
substituted. The basic structure of amfetamines and the structure of all five amfetamines 
used in this study are shown in Figure 3.1 and Figure 3.2. Most of them have pKa values 
of approximately 10. All are suitable for drug testing in non-conventional and 
conventional matrices. AF and related compounds have similar pharmacological and toxic 
effects such as increased alertness, insomnia, energy and decreased fatigue and appetite 
with enhanced mood and euphoria. The variations of AF and related compounds' 
structures have an effect on the active drugs properties, for instance psychomotor stimulant 
effects, an increased metabolic half-life and diminished hallucinogenic activity [55]. 
For medico-legal cases, particularly in relation to workplace drug testing, the effects of 
metabolically altering urinary pH and dilution of urine samples either physically or using a 
diuretic agent, must be taken in to account and this requires careful interpretation of the 
analytical results [74]. The properties of investigated amfetamines are shown in Table 3.1. 
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Figure 3.1 Amfetamine Basic Structure (P-phenyi-isopropylamine) 
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Figure 3.2 The structure of Amfetamlne(CqHl3N), Methamfetamine(ClOH15N), 
MDA(ClOH13NO2)p MDMA(CIIH15NO2) and MDEA(Cl2Hl7NO2) 
Table 3.1 Properties of Amfetamines [58] 
Drug Street Name MW PK. 
AF Bennies, speed 135.2 9.9 
MA Speed, ice, crystal, crank, meth, go, oxblood 149.2 10.1 
MDA Speed, love pill 179.2 -10 
MDMA ecstasy, XTC, Adam, M&M, MDM, E 193.2 
MDEA Eve 207.3 
MA 
CH3 
0 CH2CHNHCH3 
0 
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Enantiomers of Amfetamines 
AF, MA and all of methylenedioxy derivatives of arnfetamine drugs contain a chiral centre 
and they have a pair of enantiorners. There are two possible enantiomers for these 
compounds, d and I enantiomers designated as S-(+) and R-(-), respectively[75]. 
The enantiomers show differences in their pharmacology and toxicology such as 
metabolism rate, half-life, psychornotor performance and body disposition [55,76]. For 
example, the (S)-(+)-isomers of AF and MA have five times more potency as CNS 
stimulants than the (R)-(-)-isomer. The (S)-isomers of MDMA and MDE are responsible 
for the psychostimulant and entactogenic activities as compared with the hallucinogenic 
properties of the (R)-isomers [67,76]. It has been reported that most of the immunoassay 
and confirmation tests used can not discriminate between the two different enantiomers 
[67] 
AF and MA compounds are also available by prescription or over the counter in certain 
countries. For example in the United States, a Vicks Nasal inhaler contains the (R)-(-)- 
methamfetamine enantiomer. Therefore, the determination of the individual enantiomers is 
important and may play a role in determination of the potential source of AF or MA [74]. 
3.1.3 Amfetamine and Methamfetamine Precursor Compounds 
There are difficulties in the interpretation of AF and MA positive results in biological 
samples in clinical and forensic toxicology. These difficulties are related to at least 14 
compounds which are precursors of AF and MA. These precursors can be converted 
metabolically to AF and MA or both. A list of precursors is shown in Table 3.2. To avoid 
misinterpretation of results and distinguish between an illegal or legitimate (prescription) 
use, it is essential to consider the specific identification of metabolites and/or unchanged 
precursor drugs [74]. 
There are other precursor sources that may be converted to AF such as the monoamine 
oxidase inhibitor tranylcypromine and I-phenyl-2-nitropropane. Further tests are needed 
to prove or exclude that this is the case for these compounds [64]. There are no legal 
precursor drugs for the "designer" anifetarnines [75]. Consequently AF and MA positive 
results produced from preliminary screening (immunological identification) must be 
further investigated to identify the cause of the positive preliminary screening results to 
discriminate between an illegal or legitimate use [77]. 
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Table 3.2 Precursor Compounds to Amfetamine and Methamfetamine 
Drug name (Brand Name' 
Amphetaminil 
Benzphetamine 
Clobenzorex 
Deprenyl(selegiline) 
Dimethylamfetamine 
Ethylamfetamine 
Famprofazone 
Fencamine 
Fenethylline 
Fenproporex 
Furfenorex 
Mefenorex 
Mesocarb 
Prenylamine 
Metabolites in urine 
AF 
MA, AF, Others 
AF, Others 
MA, AF 
MA, AF, Other 
AF, Other 
MA, AF, Other 
MA, AF 
AF, Others 
AF 
MA, AF, Others 
AF, Other 
AF, Others 
AF, Others 
3.1.4 Toxicity 
Toxicity is an unwanted response to drug use that can produce undesirable side effects and 
at worst may lead to fatal poisoning. It is necessary to understand the pharmacological and 
pharmacokinetic properties of drugs to predict their toxicity [58]. Chronic AF use 
increases its toxicity and can cause mild, moderate or severe toxicity such as vomiting, 
confusion and coma respectively. Other effects include neurotoxicity and may lead to 
impairment of brain function [55]. 
When used therapeutically, AF blood concentrations are usually below 0.1ýtg/mL. In 
deaths from acute poisoning, when used alone, measured concentrations in peripheral 
blood are generally above 2pg/mL. Prescribed doses are up to 40 mg daily whereas when 
abused, the dose is estimated to be up to 2g. 
For MA, the therapeutic blood concentration is generally below 0.1 ýtg/mL. In fatalities 
when used alone, the measured concentration in peripheral blood has ranged between 0.09 
- 18 ptg/mL. When abused the dose can be up to 2g [58,79]. 
Consumption of methylenedioxy derivatives of amfetamine can cause fatal poisoning. An 
overdose can give rise to hallucinations, coma and may lead to death [80,81]. Doses of 
between 50 - 250 milligrams of MDA can result in blood concentrations up to 0.4 mg/L. 
Consumption of between 100 - 150 milligrams of MDMA has resulted in blood 
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concentrations up to 0.3mg/L. In fatalities, concentrations of greater than O. lmg/L have 
been measured in peripheral blood for traffic accident victims [58]. MDMA abuse may 
cause acute and severe toxic effects leading to complications and undesirable side-effects 
such as hyperthermia, hepatotoxicity and may cause death [82]. MDMA administration 
produced different effects such as mental and behavioural effects compared to other 
amfetamine compounds [83]. It is reported that there are associations between death 
during dancing and MDMA abuse, where a group of young adults died after ingestion of 
MDA and MDMA during their rave dancing [68]. MDEA has similar psychoactive 
effects to MDMA but at equivalent doses has less neurotoxic effects [55]. The dose 
abused is estimated to be between 30 and 100 mg [4]. 
Blood concentrations of AF and related compounds found in fatal cases either alone, with 
alcohol or other drugs are shown in Table 3.3 [84]. Also the concentrations of AF and 
related compounds found in related deaths in various biological matrices are displayed in 
Table 3.4 [85]. 
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Table 3.3 Fatal amfetamines and related compounds concentrations in blood 
Compound Blood Concentration (mg/L) 
Alone With Alcohol (EtOH) With other drugs 
AF 0.1-2.6 0.1-0.75 0.02-0.64 
n=5 n=5 n= 12 
MA 0.35 n/a n/a 
n=I 
MDA 0.04-0.05 0.12-0.30 0.15-1.2 
n=2 n=3 n=4 
MDMA 0.23 0.17-0.60 0.03-8 
n=2 n=3 n=5 
MDEA 0.77 0.22-2 2.44-4.32 
n=I I n=3 n=2 
n/a: not available 
Table 3.4 Fatal amfetamine and related compounds concentrations in different biological 
matrices 
Compound Urine Liver Kidney Brain Stomach Muscle 
(mg/L) (mg/kg) (mg/kg) (mg/kg) Contents (mg/kg) 
AF 33.4-700 11.7-45 3.9-48 3-41 21mg 4 
n=4 n=8 n=5 n =3 n=1 n=1 
3000 mg/kg 
n=1 
MA 1-398.4 0.6-174.7 0.2-87 0.2-101.8 5.8-44 mg 3.6-47.7 
n= 10 n= 19 n= 17 n= 17 n=4 n=6 
17-514.3 
mg/L 
MDA 168-175 11-13 18 10 0.25-1.7 mg n/a 
n=2 n=2 n=1 n= I n=2 
MDMA 14.3-529 6.4-39.7 12.1 13.7-17.4 96 mg/L 4.5 
n=3 n=4 n=1 n=2 n=1 n=1 
I 18 mg/kg 
n=1 I 
MDEA 20 1 1 9 15 28 52 mg/kg n/a II 
n= 1 1 n = 1 n= n=I n=l 
n/a: not available 
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3.1.5 Disposition in the Body 
Physical and chemical properties of drugs play a major role in their absorption, distribution 
and elimination [55]. 
3.1.5.1 Absorption 
There are different routes of amfetamines administration (swallowed or injected) but, AF 
itself is usually consumed orally either as the (S)-(+)-enantiomer (dexamfetamine) or the 
racemic mixture (eg. amfetamine sulphate). The tablet form of AF is the most commonly 
encountered amongst abusers. Amfetamines are rapidly and readily absorbed following 
ingestion. After a single oral administration they reach their plasma concentration peak 
within 4 hours. No significant differences between racernic and individual isomers were 
observed in pharmacokinetic parameters (Cmax and Tmax) during the absorption phase. 
While, the general routes of MA administration include the oral route, they can be injected 
intravenously, snorted ('speed') or can be smoked as (S)-(+) - methamfetamine 
hydrochloride ('ice', vapour inhalation) through a glass pipe system. It was observed that 
the plasma concentration of smoked MA was higher than its concentration if taken by the 
oral administration; bioavailability was 90% and 67% respectively. Tmax values of 
smoked and intravenous MA administration were shorter than the oral administration. I- 
2.5 hours, these for smoked and intravenous and at least 3 hours after oral administration. 
Methylenedioxy derivatives are mostly consumed orally and are absorbed into the blood 
after administration. Pharmacokinetic properties of MDEA are similar to those of MDMA 
when given orally [55]. With a typical dose (60-120 mg), MDA is more potent than 
MDMA and MDEA. The onset of effects is from 30 to 60 min for MDA and 30 min for 
MDMA and MDEA and the duration of action of MDA, MDMA and MDEA is about 8 h, 
6h and 3-4 h respectively [68]. 
3.1.5.2 Distribution 
AF and related compounds have relatively low molecular weights, are weak bases and 
have a low protein binding (around 20%). These parameters enhance their diffusion across 
cell membranes, lipid layers and tissues, consequently, increasing their accumulation and 
concentration in different compartments such as tears, saliva, sweat, hair and nails. 
Therefore, it is potentially one of the best drug groups suitable for testing in these 
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biological samples. It was noted that there was no difference in the protein binding and 
distribution volumes of AF enantiomers (S & R), while, the AF (S) enantiomer exhibits a 
faster metabolism than the (R) enantiomer. Consequently, the elimination half-life will be 
shorter for (S) enantiomer. There are similarities between volume of distribution of MA 
and AF. Concurrent use of ethanol will cause a decrease in the volume of distribution of 
MA due to ethanol displacing MA from peripheral binding. There are limitations in the 
distribution of designer amfetamines in humans after administration. The passage of AF 
and related compounds from blood to other fluids is regulated and depends on pKa and the 
pH in each biological fluid. For example, AF tends to accumulate in saliva and sweat, due 
to their pH being lower than plasma pH (7.4). It was noted that after oral ingestion, the AF 
concentration in oral fluid was higher than its concentration in plasma [55]. 
3.1.5.3 Metabolism 
3.1.5.3.1 Amfetamine 
P-hydroxyamfetamine and benzoic acid including its glycine conjugate are the main 
metabolites of AF in the body. Also, unchanged AF can be detected in urine [86]. AF is 
metabolised after absorption whereas, under normal conditions a large fraction is 
inactivated by virtue of being deaminated to phenylacetone, then oxidized to benzoic acid 
and excreted as conjugates. A small fraction of AF is converted by oxidation to 
norephedrine. Norephedrine and its precursor are p-hydroxylated [79]. The metabolic 
pathway of AF is shown in Figure 3.3. 
CH CH 330 
CH2CHNH2 
UM norephedrine amfetamine phenýacetone 
p- hydro4ation glucuronide and COOH 
and conjugation glycine conjugation 
benzoic acid 
Figure 3.3 The metabolic pathway of amfetamine in human body [79] 
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3.1.5.3.2 Methamfetamine 
The N- demethylated form of methamfetamine produces amfetamine as an active 
metabolite [79]. The other metabolic pathways of MA when converted to p-hydroxylated 
metabolites and benzoic acid are the same as for AF metabolism, but with a lower 
formation of benzoic acid than from AF [86]. The metabolic pathway of methamfetamine 
is shown in Figure 3.4. 
9H3 
CH2a-rl-K3-ý 
0- 
L" 
metonfetamine aTietamine norepheddne 
deanination, p-hydnmcylation and oonjugation 
Figure 3.4 The metabolic pathways of methamfetamine in human body [79] 
3.1-5.3.3 Methylenedioxy derivatives 
Extensive metabolism is carried out for methylenedioxy derivatives of arnfetamine. 
Monohydroxy and dihydroxy metabolites are formed [55,67]. MDA and other metabolites 
are produced from metabolism of MDMA and MDEA [58]. The metabolic pathways of 
MDMA and MDEA are shown in Figure 3.5 and Figure 3.6. Limited information is 
available for methylenedioxyamfetamine (MDA) metabolism in humans. 
CH3 CH3 
CH3 
II-I 
HO-57ý-CIH12CHNHCH3 CH2CHNHCH3 
CH2CHNH2 
HO 00 
Dihydroxy metabolite MDMA 
MDA 
Figure 3.5 The metabolic pathways of IVIDIVIA in human body [581 
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Figure 3.6 The metabolic pathways of IVIDEA in the human body [58] 
3.1.5.4 Excretion 
Excretion of AF and related compounds is pH dependent. Due to their weak basic 
properties, urinary acidification increases their excretion and urinary alkalination decreases 
it. Consequently, a significant variation of plasma half-life is exhibited. The values are 
shorter in urinary acidification and longer in urinary alkalination. It was observed that the 
excretion of unchanged MA decreased with increasing doses. Smaller amounts of 
unchanged methylenedioxy derivatives were excreted in urine than with any of the other 
amfetamine compounds [55]. Only a small amount of AF was reabsorbed under acid 
conditions, while, more AF was reabsorbed under alkaline conditions. This may explain 
the increase and decrease of AF excretion [60). 30% of AF excreted was unchanged in 24 
hour urine. This increased to 74% with acidic urine and decreased to 1% in alkaline urine. 
43% of MA was excreted unchanged in a 24 hour urine sample. A further 4-7% was 
recovered as AF. In acidic and alkaline urine, these percentages were changed. Whereas 
76% and 2% of MA was recovered unchanged in the acidic and alkaline urines 
respectively, the corresponding recoveries for AF were approximately 2% and less than 
0.1% respectively. 26% of MDMA was excreted unchanged in 24 hour urine and 1% as 
MDA after single oral dose administration (100-125 mg). 19% of MDEA was excreted 
unchanged in 32 hour urine and 28% as MDA after single oral dose administration [79]. 
3.1.6 HairAnalysis forAmfetamines 
There are many different validated analytical methods containing a variety of 
decontamination, pre-treatment, extraction, derivatisation procedures and instrumental 
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techniques which are all suitable for amfetarnines detection and have been used for 
amfetamines analysis in hair [87-112]. 
The most routine decontamination methods used for hair containing arnfetamines are acid, 
methanol, 0.1 % sodium dodecyl sulphate (SDS) with water, water with acetone and 
dichloromethane [97]. 0.1 % SDS has been used to decontaminate hair soaked in an 
aqueous solution of 10 ýtg/ml of MA hydrochloride for 24 h [19]. This was shown to 
easily and effectively remove this external contamination. A review of the literature 
showed that 0.1 % SDS and water have been used frequently as wash solvents for MA and 
its metabolites in hair [113]. 
Several pre-treatment methods have been used to extract drugs from the hair. These have 
included alkaline, acid, enzymatic and methanol pre-treatments. A GC-MS method has 
been reported for the detection of AF, MA, MDA and MDMA simultaneously in hair [93]. 
This involved digesting the hair using 1M sodium hydroxide followed by LLE and 
derivatisation with pentafluoro-propionic anhydride / pentafluoropropanol. In this case the 
limits of detection were 0.05 ng /mg for AF, MA and MDA and 0.1 ng/ mg for MDMA. 
This method showed high specificity and sensitivity for AF, MA, MDA and MDMA in 
hair samples. 
Mild enzymatic treatment (Proteinase K) with Tris buffer at a pH of 6.2 was reported to 
give good recoveries by releasing arnfetamines, cannabinoids and others drugs from hair 
by using mass spectrometric analysis (GC-MS) [28]. An advantage of enzymatic treatment 
is that it is more suitable for certain unstable drugs compared with other pre-treatment 
methods such as alkaline pre-treatment [19]. A GC-MS method was developed for the 
simultaneous analysis of amfetamines and other compounds such as opiates and cocaine in 
hair using fl-glucuronidase / aryl-sulfatase as pre-treatment method. This was followed by 
SPE and derivatisation with pentafluoro-propionic anhydride / pentafluoropropanol. The 
limits of detection for this method were less than 0.1 ng/mg for all substances and the AF 
recovery was 50% for spiked control hair [95]. 
Methanolic extraction with sonication was used by another group to extract AF and its 
methylenedioxy-derivatives (MDA, MDMA and MDEA) simultaneously from hair. 
Propionic acid anhydride (PSA) or trifluoroacetic acid anhydride (TFA) derivatisation 
reagents are used. GC-MS was used in selected ion monitoring mode for the detection. 
The limits of detection were 0.01 ng/mg for all compounds. This method proved that 
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methanolic extraction with sonication could be used successfully to extract amfetaraines 
simultaneously with other drugs such as opiates [9 1 ]. 
Two studies which compared various extraction methods for the recovery of arnfetamines 
have been reported. The first study showed that alkaline pre-treatment produced the 
highest recoveries when followed by LLE. The second study showed that acid pre- 
treatment produced the highest recoveries when followed by LLE and then SPE [92,94]. 
Many procedures used for the extraction of amfetamines from hair samples are similar to 
those used for blood analysis of amfetamines. Bond-Elut Certify SPE columns have been 
shown to give clean extracts from whole blood for AF and MA [67]. AF, MA, MDA, 
MDEA and MDEA were successfully extracted from hair using IsolutJ Confirm HCX-3 
(130 mg) SPE. The recoveries were greater than 70% for all five amfetamines [114]. LLE 
methods and SPE methods have both been used [67,75,93,95,114]. 
Derivatisation agents that have been successfully used for derivatisation of amfetamines 
following extraction of amfetamines from hair are typical of those used routinely for the 
derivatisation of amfetamines. These include trifluoroacetic anhydride (TFA), 
chlorodifluoroacetic anhydride (CDFA), heptafluoro-n-butyryl (HFB), pentafluoro- 
propionic anhydride (PFPA), N-methyl-bis-trifluoroacetamide (MBTFA) pentafluoro- 
propionic anhydride / pentafluoropropanol (PFPA / PFPOH) and propionic acid anhydride 
(PSA) [91,93,113]. 
A number of analytical methods have been reported for screening AF and related 
compounds in biological samples. These qualifying techniques have included: 
immunoassay techniques such as enzyme multiplied immunoassay technique (EMIT), 
radioinimunoassays (RIA), enzyme immunoassay (EIA), enzyme-linked immunosorbent 
assay (ELISA) and fluorescence polarization immunoassay (FPIA) [57,115-117]. 
Immunoassay has been used for screening of amfetamines in hair. These types of 
technique have included EMIT [ 118] and ELISA [ 119]. 
The confirmation techniques for amfetamines in biological specimens have included: gas 
chromatography-mass spectrometry (GC-MS), gas chromatography tandem mass 
spectrometry (GC-MS-MS), in electron impact, positive and negative chemical ionisation 
modes, GC with flame-ionisation detection (GC-FID), nitrogen-phosphorus detection 
(GC-NPD) or electron-capture detection (GC-ECD) and high-performance liquid 
chromatography with ultraviolet detection (HPLC-UV) or chemiluminescence detection 
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(HPLC-CD), capillary electrophoresis (CE), liquid chromatography mass spectrometry 
(LC-MS) and liquid chromatography-tandem mass spectrometry (LC-MS-MS) [19,115, 
120,121]. GC-MS has been frequently used for the identification of amfetamines and it is 
the most common method used for identification of amfetamines in hair [67,91,93,95]. 
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3.2 Cannabis 
3.2.1 Introduction 
The cannabis sativa L. plant which includes its sub-species (hemp 
plant, variety Indica) is the source of cannabis (marijuana and 
hashish). These are dioecious and perennial plants. They contain 
over 420 unique chemical compounds of which at least 61 
compounds are cannbinoids [1221. The female plants produce more of the main active 
constituent A? - THC than male plants. The commonly used "street" names of cannabis and 
its products are weed, grass, dope, dagga and pot [58]. The major cannabinoid substances 
in the cannabis plant are Y- THC, cannabidiol (CBD) and cannabinol (CBN). The main 
psychoactive agent identified in the plant is A? - THC which was first isolated in the 1960. 
Its acid precursor, A? -tetrahydrocannabinolic acid (A? -THCA) is not psychoactive. It 
does, however, account for most of the THC related substances present in the plant. Only 
a small amount is present as neutral THC [123]. A? -THCA is converted to active 
Y- 
THC by heat or when cannabis products are smoked (decarboxylated) [ 124]. In addition, it 
was shown only that 2 -tetrabydrocannabinol (2 -THC), 
Y 
-tetrahydrocannabivarol 
and CBN have significant psychoactive properties [125]. 
Since ancient times, the cannabis plant and its product were used for recreational, 
medicinal and religious purposes in different cultures [126]. Also, it is used as a fibre 
source (hemp) [127]. In the beginning, marijuana was taken by the inhalation of volatile 
oils generated in the smoke. There are reported usages for a number medical conditions 
including pain, anxiety, glaucoma, nausea (for cancer chemotherapy), emesis, muscle 
spasms and wasting diseases [128]. Dronabinol and Marinol are prescription forms for 2- 
THC [791. Y- THC is often present at low concentration with no psychoactive effects in 
shampoo preparations, in foodstuffs (product) such as oil, noodles, crackers and in 
beverages such as tea [129]. Cannabis material has been used in food products in different 
global markets as nutritional supplements in the last few years [130]. Due to its sedative 
and anxiolytic properties, it has been used by athletes to reduce stress [ 13 1 ]. 
The use of a high dose of cannabis can cause euphoria and relaxation followed by a 
depressant period [132]. Cannabis is available in various preparations. The concentration 
of A9 -THC depends on the particular preparation and formulation type. Marijuana, 
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hashish, oil are prepared from dried plant (herbal cannabis), resin (cannabis resin) and by 
distillation respectively. It is usually mixed with tobacco and is rarely chewed [133]. It is 
reportedly taken with other drugs such as alcohol to enhance the psychoactive effect [132]. 
The administration route of cannabis can be either oral, such as marijuana mixed with 
food, e. g. brownies, or by inhalation (smoking) [134]. Overall, the main administration 
route is smoking [13]. Cannabis is the most commonly and frequently used illegal 
substance worldwide and recent studies demonstrated that about one to two thirds of young 
people in Australia, Germany, New Zealand and the United Kingdom have tried cannabis 
at least once prior to young adulthood [135]. It ranked next to alcohol and nicotine [136]. 
In accordance with European Monitoring Centre for Drugs and Drug Addiction 
(EMCDDA), Europe, 2001, Substance Abuse and Mental Health Services Administration 
(SAMHSA), USA, 2001 and Australian Institute of Health and Welfare, Australia 2002, 
cannabis is the most widely abused drugs in these countries [137]. It was reported that 
cannabis use has the potential risk of leading to the usage of other harder illegal drugs 
[138]. It was reported in 2004 that there are approximately 300-400 million consumers of 
cannabis preparations in the world [122]. According to the BCS, cannabis was the most 
commonly used drug in 2004/5. It was estimated that 23.5% of 16 to 24 year olds in 
England and Wales used this drug in the last year [3]. 
An association between cannabis consumption and psychosis has been reported [136]. Its 
biological effect is initiated by its interaction with cannabinoid receptors such as CB1 and 
C132 which are found in mammalian tissue and widely distributed in the CNS and 
peripheral tissue [139]. There are various effects of cannabis, either acute effects such as 
loss of internal control and impairment of attention and memory especially, during 
intoxication and adverse chronic effects on cognition. This may cause cannabis 
dependence syndrome which is an inability to control or to abstain from cannabis use 
[127]. It was confirmed as a risk factor for arthritis and it is reported that intoxication 
induces aggressive behavior [133]. Dry mouth, blurred vision and ataxia (an increased 
heart rate) can be attributable to A? -THC use [140]. 
It has been reported that one in 11 cannabis users will become dependent. Cannabis 
withdrawal was characterised by different sips and symptoms such as irritability, anxiety, 
sleep disruptions, aches, and pains, which lead to difficulty in maintaining abstinence. 
Adverse effects on cognitive function were also reported and observed with heavy 
cannabis use and it was reported that pulmonary dysfunction was associated with regular 
cannabis smoking similar to regular tobacco smokers [141] 
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5-10 mg of cannabis smoked is enough to produce the effects such as euphoria, 
hallucinations and often sedation [134]. At a federal level in USA, medicinal use of 
smoked or ingested marijuana is prohibited [128]. Cannabis has been listed since January 
2004 in Class C of the Misuse of Drugs Act 1971 [3]. 
3.2.2 Chemistry 
The main active component of cannabis is A? -THC, which exists in a variety of 
stereochemical forms. These include (-)-trans-A? -tetrahydrocannabinoI isomer, also known 
as dronabinol or A? -THC. There are other cannabinoid compound isomers which have 
less potential pharmacological activity than A? -THC for instance 
Y 
-THC [140]. The 
chemical formula of A? -THC is C21H3002, its molecular weight is 314.5 and its pKa is 
10.6. It is insoluble in water [4]. The chemical structure of A? -THC is shown in Figure 
3.7. 
OH 
CH 0 
CH3 
C5Hjj 
THC 
A9 -tetrahydrocannabinol (A? -THC) 
Figure 3.7 Chemical structures of A? -THC 
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3.2.3 Disposition in the Body 
3.2.3.1 Absorption and Distribution 
A9 -THC and other cannabinoid compounds are absorbed by inhalation (smoking) or 
by 
ingestion (orally). The concentration of its metabolites will depend on the route of 
administration [58]. Y -THC is distributed widely in the body to fat and muscle and its 
concentrations in blood decline due to its lipophilic and low water solubility properties. 
Within 15 min of smoking, the peak plasma concentrations of Y -THC may exceed 50 
ng/ml and reach 200 ng/ml with higher THC doses [125]. 
3.2.3.2 Metabolism 
A? -THC is rapidly oxidized to the psychoactive metabolite 11-hydroxy-A? - 
tetrahydrocannabinol (1 1-OH-THC), which is subsequently further oxidized to the non- 
psychoactive metabolite A? -THC-COOH. Minor metabolic pathways are carried out to 
produce smaller quantities of the other metabolites 8-alpha-OH-THC and 8,1 1-dihydroxy- 
THC. A! -THC and its hydroxylated and carboxylated metabolites are conjugated with 
glucuronic acid, and are subsequently excreted in urine as water soluble compounds [79, 
130,142]. The metabolism of A? -THC is shown in Figure 3.8. 
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Figure 3.8 A? -THC and A! -THC-COOH Metabolic Pathway [79] 
Conjugation 
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3.2.3.3 Excretion 
Often cannabinoids and their metabolites are excreted as glucuronic acid conjugates, 
therefore require hydrolysis prior to analysis [142]. Conjugated and unconjugated A? - 
THC-COOH are the major metabolits found in urine samples. Y-THC and its metabolites 
A? -THC-COOH and 1 1-OH-THC are found in blood. The main compound in hair is 
Y- 
THC (13]. Within 72 hours, 70% of A? -THC dose is excreted. Approximately 40% in the 
faeces and 30% in the urine, A small amount of unchanged A? -THC is excreted in urine 
[79]. It is reported that the urinary excretion half-life of A? -THC is 3-13 days and that of 
the main urinary metabolite A? -THC-COOH is 12 -25 days, depending on frequency of use 
[125]. 
It is reported that only A? -THC is detectable in saliva and sweat. The other metabolites are 
rare. CBN, THC, CBD and A? -THC-COOH are detectable in hair, but A? -THC-COOH is 
at very low concentrations, while in meconium only A? -THC-COOH is detectable [1431. 
3.2.4 Hair Analysis for Cannabinoids 
A number of methods have been described regarding cannabinoids in hair samples [122, 
129,134,144-157]. The first method to determine 2-THC and A! -THC-COOH inhuman 
hair used gas chromatography/mass spectrometry for detection. Dichloromethane was 
used to decontaminate the hair. This was followed by alkaline pre-treatment using IN 
NaOH, LLE (n-hexane/ethyl acetate) and derivatisation when was carried out using 
PFPA/PFP-OH. The limit of detection of both A? -THC and A? -THC-COOH were 0.1 
ng/mg and their recoveries were 75 and 80%, respectively [158]. 
A sensitive analytical method was developed for quantitative analysis of A? -THC, A? -THC- 
COOH, CBN and CBD in human hair. Internal standards used were ketarnine for CBN 
and CBD, and ketoprofen for A? -THC and A? -THC-COOH. fl -glucuronidase / 
arylsulfatase was used as pre-treatment method. LLE was used for the extraction and 
pentafluoropropionic anhydride (PFPA) and pentafluoropropanol (PFPOH) for 
derivatization. Gas chromatography/mass spectrometry detection, with electron impact 
ionisation (GC-MS-EI) was used for the analysis of all the compounds. The concentrations 
of the main metabolite of A? -THC, i. e. A? -THC-COOH are very low in hair. For this 
reason gas chromatography/mass spectrometry, in negative ion chemical ionisation mode 
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(GC-MS-NCI) using methane as the reagent gas was used to detect A? -THC-COOH. 
Extraction recoveries ranged from 80.9 to 104.0% for 2-THC, 76.7-95.8% for CBN, 
71.0-94.0% for CBD and 85.9-100.0% for A! -THC-COOH by GC-MS-NCI and 77.7- 
98.9% by GC-MS-EI. LOD's were 20.00 pg/mg hair for A? -THC and cannabidiol, 50.00 
pg/mg hair for cannabinol and 0.50 ng/mg hair for A? -THC-COOH by GC-MS-El, while 
A? -THC-COOH by GC-MS-NCI was 5.00 pg/mg hair [ 15 3]. 
The presence of A? -THC-COOH in hair shows conclusive proof of cannabis use and for 
this reason its identification in hair is important. The finding of the parent drug alone 
could be as a result of environmental (passive) contamination. Since, the concentrations of 
the main metabolite of A? -THC, i. e. A? -THC-COOH are very low in hair, high sensitivity 
techniques, high-volume injection and good clean-up methods are required [122,153]. 
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4 Analysis of Arnfetarnines and Cannabinoids 
4.1 Aim 
The purpose of the following study was to identify amfetamines and cannabinoids 
simultaneously in hair samples using a single extraction procedure. It was necessary to 
investigate the pre-treatment steps for all of the compounds of interest to optimize a 
method for this purpose. Four pre-treatment procedures were chosen (enzymatic, alkaline, 
acid and methanol) for the comparison study. The optimised method giving the highest 
recoveries would then be selected to analyse these drugs in hair. The SPE method 
developed by Chen et al using Bond Elut Certify columns has been shown to be successful 
in extracting a range of drugs (acidic, neutral and basic drugs) in whole blood with good 
recoveries [159]. This method has also been adapted for the extraction of drugs in 
meconium [ 160] and in oral fluid samples [ 16 1] and could be used as a clean-up method to 
extract drugs from pre-treated hair. For this reason this SPE method was selected 
following pre-treatment by the four different methods. The best pre-treatment method 
would then be validated. 
4.1.1 Experimental 
4.1.1.1 Chemicals and Reagents 
AF, MA, MDA, MDMA, MDEA, A? - THC and A? - THC-COOH and their deuterated 
internal standards, AF-ds, MA-d5, MDA-d5, MDMA-d5, MDEA-d5, A? - THC-d3 and A? - 
THC-COOH-d3 were purchased from Radian (Teddington, LTK). The derivatising reagents 
pentafluoropropionic anhydride (PFPA) and pentafluoropropanol (PFPOH), 9- 
glucuronidase (activity =86.900 units/ml, sulfatase activity = 2,210 units/ml) and sodium 
dodecyl sulphate (SDS) were purchased from Sigma (Dorest, UK) and Bond Elut 
Certif)Jm from Crawford Scientific (Strathaven, UK). HPLC grade solvents, methanol 
(MeOH), acetone, chloroform (CHCIA distilled water (DI H20), ethyl acetate (EtOAc), 
hexane, dichloromethane, analytical-grade ammonium hydroxide, glacial acetic acid, 
potassium-dihydrogen phosphate, sodium hydroxide (NaOH), hydrochoric acid (HCI) and 
tartaric acid were obtained from Merck (Poole, UK). 
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4.1.1.2 Stock Standards 
All stock standards had concentrations of 100 gg/mI. These were stored in the freezer at - 
20 'C. An amfetamine working standard solution was prepared by measuring 50 [tI of 
stock standards of AF, MA, MDA, MDMA and MDEA into a large vial. This was made 
up to 5 ml with methanol to give a1 gg/ml combined amfetamines working standard. A 
cannabinoids working standard solution was prepared by measuring 50 PI of stock 
standards of A? - THC and A? - THC-COOH into a large vial. This was made up to 5 ml 
with methanol to give aI gg/ml combined cannabinoid working standard. Amfetamine 
and cannabinoids deuterated internal standard solutions were similarly prepared using AF- 
d5, MA-d5, MDA-d5, MDMA-d5, MDEA-d5, and A? - THC-d3 and A? - THC-COOH-d3 to 
give a combined arnfetamine deuterated working standard and a combined cannabinoid 
deuterated working standard at 1 gg/ml . 
4.1.1.3 Instrumentation (GC-MS) 
A ThermoQuest Trace GC with a Finnigan Trace MS was used, fitted with a HP-5 
capillary column (30 in x 0.32 min x 0.25 gm film thickness). This was temperature 
programmed from 100 to 300 'C at a rate of 12 'C / minute and held at 300 'C for 5 min. 
The injector temperature was 280 'C. The splitless injection mode was used. The carrier 
gas used was helium. The temperature of the source and interface were 200 OC and 250'C 
respectively. The emission current was 350 gV. The injection volume was I gl. The 
ionisation mode was electron impact with an electron energy of 70 eV. 
4.1.1.4 Identification of Retention Times and Fragmentation 
In order to identify the retention times and mass fragments of each compound and its 
deuterated standard, 100 [tl of arnfetarnines working standard solution and 100 1Al of 
deuterated amfetamines working standard solution all at 1 gg/ml were measured into a vial 
along with 100 gl (1 mg/ml) of tartaric acid in ethyl acetate. The solvent was evaporated 
to dryness under a stream of nitrogen at room temperature and the residue was derivatised 
using 60 gl of PFPA / EtOAc (0.5: 1 v/v) at 60 OC for 30 minutes. This was then 
evaporated under nitrogen and reconstituted in 30 gI EtOAc, 1 gl of which was injected for 
analysis by GC-MS. 
100 gI of cannabinoids working standard solution and 100 gI of deuterated cannabinoids 
working standard solution all at 1 gg/ml were measured into a vial. The solvent was 
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evaporated to dryness under a stream of nitrogen at room temperature and the residue was 
derivatised using 60 gl of PFPA / PFPOH (1: 0.75 v/v) at 60 OC for 30 minutes. This was 
then evaporated under nitrogen and reconstituted in 30 gl EtOAc, 1 gl of which was 
injected for analysis by GC-MS. 
Derivatising agents which were selected for the above analysis were those that are used 
routinely in the Forensic Medicine & Science laboratory, University of Glasgow for the 
identification and measurement of amfetamines and cannabinoids. Analyses were 
perfonned using repetitive full scan to identify the retention times and mass fragments of 
each compound and their deuterated standards. 
4.1.1.4.1 Results 
The retention times and mass fragments were identified. Good peak shape, good 
chromatographic resolution and sensitivity were obtained for each compound. The 
retention times and ions for each compound are shown in Table 4.1. The underlined ions 
were used for quantitation in further analyses. The chromatograms and mass spectra for 
each compound are shown in Figure 4.1, Figure 4.2, Figure 4.3, Figure 4.4, Figure 4.5, 
Figure 4.6, Figure 4.7, Figure 4.8, Figure 4.9, Figure 4.10, Figure 4.11, Figure 4.12, Figure 
4.13, Figure 4.14, Figure 4.15, Figure 4.16, Figure 4.17, Figure 4.18, Figure 4.19, Figure 
4.20 and Figure 4.21. 
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Table 4.1 The retention times (tR), derivatised analyte ions (m/z) and their cleuterated 
standards 
Analyte 
Retention 
time (min) 
Main Tons 
(m/Z) Figures 
AF 4.34 91,118,190 Figure 4.1 and Figure 4.8 
AF-ds 4.30 194 Figure 4.1 and Figure 4.15 
MA 5.52 118,160,204 Figure 4.2 and Figure 4.9 
MA-d5 5.48 208 Figure 4.2 and Figure 4.16 
MDA 7.86 135,162,325 Figure 4.3 and Figure 4.10 
MDA-d5 7.83 330 Figure 4.3 and Figure 4.17 
MDMA 8.96 135,204,339 Figure 4.4 and Figure 4.11 
MDMA-d5 8.93 344 Figure 4.4 and Figure 4.18 
MDEA 9.31 190,21&353 Figure 4.5 and Figure 4.12 
MDEA-d5 9.28 223 Figure 4.5 and Figure 4.19 
A! -THC 12.76 377,417,460 Figure 4.6 and Figure 4.13 
A! -THC A3 12.74 380 Figure 4.6 and Figure 4.20 
A! -THC-COOH 14.43 445,459,622 Figure 4.7 and Figure 4.14 
A! -THC-COOH-d3 14.41 625 Figure 4.7 and Figure 4.21 
*The underlined ions were used for quantitation 
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Figure 4.1 GC-MS Chromatograms of PFP derivatives of AF and AF-d5 
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Figure 4.2 GC-MS Chromatograms of PFP derivatives of MA and MA -d5 
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Figure 4.3 GC-MS Chromatograms of PFP derivatives of MDA and MDA-d5 
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Figure 4.4 GC-MS Chromatograms of PFP derivatives of MDMA and MDMA-d5 
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Figure 4.5 GC-MS Chromatograms of PFP derivatives of IVIDEA and MDEA-ds 
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Figure 4.6 GC-MS chromatograms of PFP / PFPOH derivatives of Y-THC and L! -THC -d3 
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Figure 4.7 GC-MS chromatograms of PFP / PFPOH derivatives of Y -THC-COOH and 
THC-COOH-d3 
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Figure 4.8 Full scan Mass Spectrum of PFP derivative of AF 
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Figure 4.9 Full scan Mass Spectrum of PFP derivative of MA 
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Figure 4.10 Full scan Mass Spectrum of PFP derivative of MDA 
Figure 4.11 Full scan Mass Spectrum of PFP derivative of MDMA 
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mlz 
Figure 4.12 Full scan Mass Spectrum of PFP derivative of MDEA 
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Figure 4.13 Full scan Mass Spectrum of PFP derivative of 2-THC 
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M/z 
Figure 4.14 Full scan Mass Spectrum of PFP / PFPOH derivative of L? -THC-COOH 
miz 
Figure 4.15 Full scan Mass Spectrum of PFP derivative of AF-ds 
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Figure 4.16 Full scan Mass Spectrum of PFP derivative of MA-ds 
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Figure 4.17 Full scan Mass Spectrum of PFP derivative of MDA-ds 
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m/z 
Figure 4.18 Full scan Mass Spectrum of PFP derivative of MDMA-ds 
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Figure 4.19 Full scan Mass Spectrum of PFP derivative of MDEA-ds 
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Figure 4.20 Full scan Mass Spectrum of PFP derivative of h! -THC -d3 
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Figure 4.21 Full scan Mass Spectrum of PFP I PFPOH derivative of THC-COOH-d3 
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4.1.1.5 Optimisation of Derivatisation 
In order to optimise the derivatisation procedure for amfetamines and cannabinoids, 100 gl 
of amfetamines standard solution, cannabinoids standard solution and their deuterated 
standards all at 1 gg/ml were added to a vial and prepared in duplicate. The derivatisation 
was carried out at three different ratios of PFPA / EtOAc (2: 1,1: 2,1: 1) for amfetamines 
and three different ratios of PFPA / PFPOH (1: 1,1: 0.75,1: 2) for cannabinoids. 
4.1.1.5.1 Results 
All chromatograms gave good peak shape, but the use of different ratios of PFPA / EtOAc 
and PFPA / PFPOH gave different intensities for the drugs of interest. The quantitation ion 
was used to assess the intensity. The results are presented in Table 4.2. PFPA / EtOAC 
(2: 1 v/v) gave the highest intensity for all the five amfetamines (AF, MA, MDA and 
MDEA) and this ratio was selected for amfetamines derivatisation. 
PFPA / PFPOH (1: 0.75 v/v) was selected for the cannabinoids because the highest 
intensity ratio was achieved for A? -THC. PFPA / PFPOH (1: 1 v/v) gave the highest 
intensity for A? -THC-COOH. However, there was little difference observed between this 
ratio and the one at 1: 0.75. The complete results are presented in Table 4.3. 
Therefore, the extracted solution by SPE was evaporated at room temperature under a slow 
flow of nitrogen and derivatised using 60 ýtl of PFPA / EtOAc ( 2: 1 v/v) for amfetarnines 
and PFPA / PFPOH ( 1: 0.75 v/v) for cannabinoids in a sealed vial which was vortexed 
and then placed into a 60 'C heating block for 30 minutes. After derivatisation was 
completed, the reagents were evaporated under nitrogen and reconstituted in 30 ýd EtOAc, 
1 ýtl of which was injected for analysis by GC-MS. 
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Table 4.2 The mean peak area of amfetamines with different ratios of derivatising agent 
(PFPA I EtOAc) 
Derivatising Reagent 
Ratio 
PFPA: EtOAc 
2: 1 
1: 2 
1: 1 
Av rage Peak Area 
AF MA MDA MDMA 
190 MIZ 204 m/z 325 m/z 339 m/z 
2090826 5102208 776362 357643 
1554504 3993772 460207 224711 
1524217 1296367 714397 329090 
MDEA 
218 mlz 
10384886 
3763808 
6012077 
Table 4.3 The mean peak area of cannabinoids with different ratios of derivatising agents 
(PFPA / PFPOH) 
Derivatising Reagent 
Ratio Avera 
PFPA: PFPOH Y-THC 
377 m/z 
1: 1 2768566 
1: 0.75 3349724 
1: 2 1284828 
4.1.1.6 Buffers and Solutions 
0.1 Mphosphate buffer, pH 60 
of Peak Area Ratios 
I A7-THC-COOH 
622 m/z 
43103 
42565 
18808 
6.81 g of potassium dihydrogen phosphate (KH2PO4, FW =136.09) was weighed into a 0.5 
litre volumetric flask and approximately 450 ml of distilled water was added. The pH was 
adjusted to 6.0 (+/ - 0.1) with 10.0 M potassium hydroxide solution while stirring and the 
solution was made up to 0.5 litre with distilled water and was stored at 5 'C. The solution 
was discarded after one month. 
0.01 M acetic acid, pH 3.3 
57.2 ýd of glacial acetic acid was pipetted into a 100 ml volumetric flask and DI H20 was 
added up to the 100 ml mark. This was mixed well and stored at room temperature. The 
solution was discarded after two months. 
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Acetone/ Chloroform (1: 1 v/v) 
50 ml of acetone and 50 ml chloroform were measured into a bottle, mixed well and 
sonicated for 10 minutes, stored at room temperature and discarded afler one month. 
EtOAc /concentrated ammonia (98: 2) 
98 ml EtOAc was measured into a bottle and 2 ml of concentrated ammonia solution 
(ammonium hydroxide) was added carefully. This was prepared under a fume hood and 
sonicated for 10 minutes. This solution was made up fresh every day. 
Tartaric Acid in EtOAc (I mglml) 
5 milligrams of tartaric acid were weighed into a large vial and 5 ml of EtOAc was added. 
This was sonicated for 10 minutes, stored at room temperature and discarded afler one 
month. 
IMsodium hydroxide (NaOH) 
4.0 grams of NaOH (MW 40.0) pellets were measured into a 100 ml volumetric flask and 
made up to the 100 ml mark with DI H20. This was mixed thoroughly, stored at room 
temperature and discarded after six months. 
0.1 M hydrochoric acid (HC1) 
4.2 ml concentrated HCI was added to 400 ml of DI H20 and diluted to 500 ml with DI 
H20 and mixed thoroughly. This was stored at room temperature and discarded after six 
months. 
n-hexane 1EtOAc (9: 1 v/v) 
90 ml hexane was measured into a bottle and added 10 ml. EtOAc and mixed well, stored at 
room temperature and discard after one month. 
n-hexane 1EtOAc (8: 2 v/v) 
80 ml hexane was measured into a bottle and to this 20 ml EtOAc was added and mixed 
well. This was stored at room temperature and discarded after one month. 
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4.1.1.7 Preparation and Decontamination of Hair 
Drug free hair was obtained from volunteers and tested by the method, which has been 
used by Department of Forensic Medicine and Science, University of Glasgow, to show it 
was negative for amfetamines and cannabinoids. In this study, the decontamination 
procedure chosen was one that had been used routinely for hair analysis by Forensic 
Medicine & Science, University of Glasgow. Blank hair and case hair samples were 
decontaminated using the following wash steps: 
Immersion in 0.1 % SDS detergent, sonication for 15 minutes. Solution discarded 
(X 1) 
Immersion in DI H20, sonication for 15 minutes. Solution discarded. (x 2) 
o Immersion in dichloromethane, sonication for 10 minutes. Solution collected for 
analysis (x 3) 
If the last wash fraction of a case hair sample was positive for any of the drugs the 
dichloromethane wash step was repeated until the wash fraction was free of drugs. Once 
the last wash with dichloromethane had tested negative for the analytes of interest or was 
less than its limit of detection, the hair samples (both blank and case samples) were 
allowed to air dry overnight and were then weighed. Washing takes place prior to cutting 
the hair. After drying the hair overnight at room temperature, the hair samples were cut 
into small segments (1-2 mm) and an appropriate amount weighed out into 10-ml screw- 
capped tubes. 
4.1.1.8 Hair Pretreatment Methods 
To liberate the drug from the hair matrix, the following pre- treatment methods were used: 
Alkaline pre-treatment: Hair was incubated in I ml of IM NaOH at 95 'C for 10 
minutes. After cooling to room temperature, I ml of 1M HCI was added to neutralize the 
solution and 2 ml of phosphate buffer, pH 6.0 was added. After adjusting with 1M NaOH 
to pH 6.0 and centrifuging for 20 minutes at 2000 rpm, the supernatant was transferred to a 
clean large vial for extraction. 
fl-Glucuronidase pre-treatment (helix parnatia, 86,900 unit / ml): Hair was incubated in 
lml of phosphate buffer pH 6 and 50 [d fl-glucuronidase solution at 45 'C for 2 hours. 
After cooling to room temperature, 2 ml of phosphate buffer pH 6.0 was added, vortex 
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mixed and centrifuged for 20 minutes at 2000 rpm. The supernatant was transferred to a 
clean large vial for extraction. 
Methanol pre-treatment: Hair was incubated in I ml of (MeOH) at 45 OC for 18 hours. 
After cooling to room temperature, the MeOH was transferred into a clean tube, 4 ml of 
phosphate buffer pH 6.0 was added, vortex mixed and centrifuged for 20 minutes at 2000 
rpm. The supernatant was transferred to a clean large vial for extraction. 
Acid pre-treatment: Hair was incubated in Iml of dilute acid (0.1 HCI) at 45 T for 12 
hours. After cooling to room temperature, I ml of 0.1 M NaOH was added to neutralize the 
solution and 2 ml of phosphate buffer pH 6.0 was added. This was centrifuged for 20 
minutes at 2000 rpm and the supernatant was transferred to a clean large vial for 
extraction. 
4.1.1.9 Solid Phase Extraction Method for Amfetamines and Cannabinoids 
The SPE method developed by Chen et al was chosen as the clean-up method because it 
has been used to isolate a broad range of drugs (acidic, neutral and basic drugs) from 
whole blood with acceptable recoveries. Most drugs (acidic, neutral and basic ) are 
retained on the column at pH 6 [159]. This method was investigated as a possible clean-up 
step for the combined extraction of amfetamines and cannabinoids in hair. 
SPE was carried out using Bond Elut CertifyTm columns. The SPE columns were 
conditioned with 2 ml of methanol and 2 ml of phosphate buffer (pH 6, OAM) in 
preparation to receiving an aqueous sample. The samples were applied to the column, 
taking at least two minutes to pass through the column. The column was then washed with 
1 ml DI H20 to remove endogenous and interference components. 0.5 ml 0.01 M acetic 
acid (pH 3.3) was added to adjust the pH of extraction. It was reported that pH 3.3 was the 
best choice to adjust the extraction system to elute the acids or basic drugs selectively from 
the column. The column was dried under full vacuum for 5-10 minutes and 50 [LI of 
methanol was added. This was dried for a further 3 minutes under full vacuum. The 
cannabinoids were eluted with 3.5 ml of acetone/chloroform (1: 1 v/v) [162]. The 
amfetamines were eluted with 2 ml of 2% concentrated ammonia in ethyl acetate [159, 
162]. 100 R1 tartaric acid was added to prevent amfetamines from evaporating [ 114]. The 
elution solutions were evaporated at room temperature under a slow flow of nitrogen and 
the acetone / chloroform fraction residue was derivatised as described in section 4.1.1.5.1 
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for cannabinoids and the EtOAc / ammonia fraction residue was derivatised as described in 
section 4.1.1.5.1 for amfetamines. 
Calibration Curves 
The purpose of this initial experiment was to investigate the simultaneous extraction of 
amfetamines and cannabinoids using the four pre-treatment-methods. Each of the pre- 
treatment methods described in section 4.1.1.8 were used on 30 mg hair samples which 
were spiked with 5,10,25,50,100 and 200 ýd AF, MA, MDA, MDMA, MDEA, A? -THC 
and 2 -THC-COOH of working standard solution and 100 ýtl of deuterated working 
standard, all at 1 gg/ml to give a six point calibration curve. A blank hair sample without 
standard or internal standard and a blank hair sample with only 100 gl of internal standard 
were also prepared and extracted. The solid phase method described in 4.1.1.9 was used to 
clean up the hair samples. These were derivatised as described in sections 4.1.1.5.1. 
4.1.1.10.1 Calibration Curves Result 
The peak area ratios (PAR) of AF, MA, MDA, MDMA and MDEA to their deuterated 
internal standards were calculated and calibration curves of PAR against concentration 
were plotted for each compound. The results demonstrated that all extraction methods 
worked well for amfetamines which had been added to hair. The linearities are 
summarised in Table 4.4 and Table 4.5, and shown in Figure 4.22, Figure 4.23, Figure 
4.24, Figure 4.25 and Figure 4.26. 
In contrast, the cannabinoid results were poor. The detection limits for these appeared to 
be low as shown by their low peak areas in comparison to unextracted standards. 
Calibration curves could not be plotted for these and further investigation was required to 
improve the recovery. 
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Table 4.4 Linearity of amfetamines with different extraction methods 
An Concentration 
1.000 
1.000 
0.999 
0.999 
1.000 
Correlation coefficients 
AF 
MA 
MDA 
MDMA 
MDEA 
5- 200 
5- 200 
5- 200 
5- 200 
5- 200 
Alkaline Acid 
0.998 0.994 
0.997 0.994 
0.994 0.999 
0.996 0.999 
0.997 1.000 
Methanol 
0.998 
1.000 
0.992 
0.999 
1.000 
Table 4.5 Linear Values of amfetamines with different extraction methods 
Analyte Enzy matic Alkaline Acid Methanol 
- Intercept Slope Intercept Slope Intercept Slope Intercept Slope 
AF 0.0267 0.0121 -0.0100 0.0097 0.0087 0.0092 -0.0494 0.0082 
MA 0.0109 0.0074 -0.0159 0.0097 0.0360 0.0071 -0.0382 0.0125 
MDA 0.0360 0.0121 -0.0524 0.0107 -0.0379 0.0120 -0.1477 0.0145 
MDMA 0.0164 0.0124 0.0124 0.0103 -0.0517 0.0120 -0.0037 0.0113 
MDEA 0.0037 0.0017 -0.0295 0.0118 -0.0219 0.0095 -0.0067 0.0080 
AF 
o 2.5 
cu 2- W- 
a' 1.5 
Cc 0.5 
0 
-0.5 
1 
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Enzymatic 
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Linear (Acid) 
Linear ( Methanol) 
so 
Figure 4.22 Calibration curve of AF with different pre-treatment methods 
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Figure 4.23 Calibration curve of MA with different pre-treatment methods 
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Figure 4.24 Calibration curve of MDA with different pre-treatment methods 
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Figure 4.25 Calibration curve of MDMA with different pre-treatment methods 
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Figure 4.26 Calibration curve of MDEA with different pre-treatment methods 
Diagnostic Use ofHair Analysisfor the Detection of Misuse ofAmfetamines and Cannabinvids 
0 50 100 150 200 250 
50 100 150 200 250 
Concentration (ng) 
Chapter Four: Analysis of Amfetamines and Cannabinoids Page 80 
4.1.1.11 SPE Recovery Study 
As a result of the difficulties in plotting the cannabinoids calibration curves, a recovery 
study of the SPE method was investigated for all compounds of interest. This included the 
recovery of AF, MA, MDA, MDMA, MDEA, A? -THC and A? -THC-COOH without the 
presence of hair using the SPE method alone. 200 pI of amfetamines working standard 
solution and 200 pI of cannabinoids working standard solution all at 1 gg/ml were 
measured into a test tube. 3 ml of 0.1 M phosphate buffer, pH 6 were added and the 
solution was vortex mixed. This was prepared in triplicate. The solutions were extracted 
using the SPE method described in section 4.1.1.9.200 pl of deuterated amfetamines 
standard solution and 200 gl of deuterated cannabinoids standard solution, all at I gg/ml 
were added after extraction. The solution was evaporated to dryness and derivatised as 
described in section 4.1.1.5.1. 
4.1.1.11.1 Recovery Study Results 
The recoveries were determined by comparing the PAR of extracted standards to the PAR 
of the unextracted standards. The results showed that the SPE was successful for all of the 
compounds and the recovery was greater than 64 % for all of the compounds. The results 
are represented in Table 4.6. 
Table 4.6 Recovery of cannabinolds and arnfetamines by SPE at pH 6 without hair (n = 3) 
Analyte Mean Peak Area Ratio S. D %CV 
_ 
%Recovery 
Ext Uext Ext Uext Ext I Uext 
A! - THC 0.10 0.16 0.01 0.01 7.9 3.4 64.2 
2 -THC-COOH 1.11 1.54 0.23 0.06 20.4 3.8 72.1 
AF 1.31 1.73 0.07 0.35 5.5 20.1 75.4 
MA 0.93 1.20 0.11 0.05 11.6 4.2 77.6 
MDA 0.96 1.17 0.12 0.00 12.8 0.4 82.2 
MDMA 1.35 1.65 0.20 0.01 14.9 0.3 81.5 
MDEA 0.13 0.15 0.01 0.00 5.6 2.2 89.0 
V, xt: txtractecl, Uext: Unextracted 
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4.1.1.12 Recovery Study Using Alkaline Digestion Followed by SPE 
The recoveries of AF, MA, MDA, MDMA and MDEA, A? -THC and 
Y 
-THC-COOH from 
spiked hair using alkaline pre-treatment followed by SPE were investigated. Alkaline pre- 
treatment was chosen initially because of its ability to completely dissolve the hair 
matrices and therefore to release the drugs completely from authentic hair samples [163]. 
200 gI of amfetamines working standard solution and 200 gI of cannabinoids working 
standard solution all at I gg/ml were measured into a test tube containing 30 mg of blank 
hair. 1 ml of IM NaOH was added and the solution was vortex mixed. The solution was 
incubated at 95 T for 10 minutes. After cooling to room temperature, I ml of 1M HCL 
was added to neutralize the solution and 2 ml of phosphate buffer, pH 6.0 was added. 
After adjusting to pH 6.0 with 1.0 M NaOH, the solution was centrifuged for 20 minutes at 
2000 rpra and the supernatant transferred to a clean large vial for extraction as described in 
section 4.1.1.9. This was prepared in triplicate. The deuterated working standards were 
added after the extraction. The solution was evaporated to dryness and derivatised as 
described in section 4.1.1.5.1. 
4.1.1.12.1 Recovery Results 
The recoveries were determined by comparing the PAR of extracted spiked blank hair (30 
mg) standards to the PAR of the unextracted standards. The results showed that the 
recovery of cannabinoids had significantly decreased when alkaline pre-treatment was used 
followed by SPE. On the other hand the amfetamines were not affected. The results are 
represented in Table 4.7. 
Table 4.7 Recovery of cannabinoids and amfetamines by alkaline pre-treatment (n = 3) 
Analyte Mean Peak Area Ratio S. D %CV 
Ext Uext Ext I Uext Ext I Uext 
A? - THC 0.21 1.50 0.04 0.11 18.3 7.1 
h? -THC-COOH 0.24 2.04 0.04 0.35 18.3 17.4 
AF 1.42 1.77 0.05 0.03 3.8 1.8 
MA 0.58 0.66 0.05 0.03 8.0 4.8 
MDA 0.75 0.90 0.01 0.03 0.7 3.4 
MDMA 0.89 1.14 0.02 0.05 2.7 4.2 
MDEA 0.11 0.13 0.00 0.01 
1 
1.3 4.3 
Ext: Extracted, Uext: Unextracted 
%Recovery 
13.8 
11.9 
80.2 
88.7 
82.8 
77.9 
80.7 
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Conclusion 
The low recoveries obtained for cannabinoids after alkaline pre-treatment followed by SPE 
showed that the method was not sufficiently sensitive for the detection and quantification 
of cannabinoids in hair. Consequently, the method required further investigation to 
improve the recovery of the cannabinoids by this proposed method. Also, the inability to 
plot calibration curves for all pretreatment methods showed that further investigation was 
needed. 
4.1.1.14 Method Modification for Cannabinoids 
4.1.1.14.1 Change in Eluent 
Further investigations were carried out with a minor modification of the method by using 
four different eluents for the cannabinoids. These were acetone/chloroform (1: 1 v/v), 
hexane / EtOAc (9: 1 v/v), hexane / EtOAc (8: 2 v/v) and methanol. Other studies have 
used different eluents to elute cannabiniods at pH 6 by using Bond Elut Certify SPE 
columns. These gave acceptable recoveries from saliva, urine and plasma. For this reason, 
the eluents hexane / EtOAc (9: 1, v/v), hexane / EtOAc (8: 2, v/v) and methanol were used 
[164,165]. 
200 pI of amfetamines working standard solution and 200 gl of cannabinoids working 
standard solution all at 1 gg/ml were measured into a test tube containing 30 mg of blank 
hair. I ml of IM NaOH was added and the solution was vortex mixed. The solution was 
incubated at 95 'C for 10 minutes. After cooling to room temperature, 1 ml of 1M HCI 
was added to neutralize and 2 ml of phosphate buffer, pH 6.0 was added. After adjusting 
to pH 6.0 with 1.0 M NaOH, the solution was centrifuged for 20 minutes at 2000 rpm and 
the supernatant transferred to a clean large vial for extraction as described in section 
4.1.1.9. The acetone / chloroform step was replaced with hexane / EtOAc (9: 1 v/v), 
hexane / EtOAc (8: 2 v/v) or methanol to elute the cannabinoids. Each eluent was tested in 
triplicate. The solution was evaporated to dryness and derivatised as described in section 
4.1.1.5.1. The deuterated working standard was added after extraction, prior to 
derivatisation. 
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4.1.1.14.1.1 Results 
The recovery of A? -THC did not significantly improve with the change in the eluents and 
also gave poor reproducibility as shown by the high % CVs. The recovery of the A? -THC- 
COOH was approximately three times higher using eluent Hexane / EtOAc (8: 2 v/v) than 
the original method using acetone/chlorofonn with good % CV reproducibility. The 
methanol eluent did not elute the target compounds. The recoveries of anifetamines were 
not affected when the cannabinoids eluent changed. The complete results are shown in 
Table 4.8, Table 4.9, Table 4.10, Table 4.11, Table 4.12, Table 4.13 and Table 4.14. 
Table 4.8 Recovery of A! -THC with different eluents at pH 6 (n=3) 
Eluent 
Acetone / Chloroform (1: 1 vIv) 
Hexane I EtOAc (9: 1 v/v) 
Hexane I EtOAc (8: 2 vIv) 
Methanol 
Ext: Extracted, Uext: Unextracted 
A9- THC 
Mean Peak S. D %CV 
Area Ratio 
II 
%Recovery 
Ext Uext Ext I Uext I Ext I Uext I ----F -Uext 
0.02 1 0.13 1 0.03 1 0.01 1 14.9 1 4.3 1 12.8 
0.02 0.13 0.01 0.01 35.9 4.3 13.9 
0.02 0.13 0.01 0.01 28.6 4.3 14.6 
0.00 
- 
0.13 
- 
0.00 
- 
0.01 
- 
0.0 4.3 0.0 
Table 4.9 Recovery of Y-THC-COOH with different eluents at pH 6 (n=3) 
Eluent 
Acetone / Chloroform (1: 1 v/v) 
Hexane I EtOAc (9: 1 v/v) 
Hexane I EtOAc (8: 2 v/v) 
Methanol 
Ext: Extracted, Uext: Unextracted 
9 A -THC-COOH 
Mean Peak S. D %CV 
Area Ratio 
Ext Uext Ext Uext Ext Uext 
0.20 1.66 0.04 0.21 17.1 12.4 
0.06 1.66 0.01 
0.54 1.66 0.03 
0.00 1.66 0.00 
0.21 19.4 12.4 
0.21 5.7 12.4 
0.21 0.0 12.4 
%Recovery 
12.4 
3.8 
32.3 
0.0 
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Table 4.10 Recovery of AF with different eluents at pH 6 (n=3) 
AF 
Eluent 
Acetone / Chloroform (1: 1 vIv) 
Hexane / EtoAc (9: 1 v/v)) 
Hexane I EtoAc (8: 2 v/v) 
Methanol 
Ext: Extracted, Uext: Unextracted 
Mean Peak 
Area Ratio 
S. D CV 
%Recovery 
-E -xt T -ue xt Ext I Llext Ext I Llext I 
1.97 1 2.56 1 0.23 1 0.29 1 12.9 1 11.3 1 76.9 
2.09 2.56 0.25 0.29 11.9 11.3 81.5 
2.01 2.56 0.11 0.29 5.6 11.3 78.5 
1.85 2.56 0.11 0.29 6.1 11.3 72.5 
Table 4.11 Recovery of MA with different eluents at pH 6 (n=3) 
MA 
Eluent 
Acetone / Chloroform (1: 1 v/v) 
Hexane EtoAc (9: 1 v/v)) 
Hexane EtoAc (8: 2 v/v) 
Methanol 
Ext: Extracted, Uext: Unextracted 
Mean Peak S. D % CV Area Ratio 
II 
%Recovery 
Ext Uext Ext I Uext I Ext I Uext I ----F-Uex 
0.81 1 1.04 1 0.11 1 0.13 1 17.4 1 12.6 1 78.1 
0.79 1.04 0.03 0.13 3.9 12.6 75.5 
0.82 1.04 0.01 0.13 1.7 12.6 79.1 
0.75 1.04 0.08 0.13 10.7 12.6 71.7 
Table 4.12 Recovery of MDA with different eluents at pH 6 (n=3) 
Eluent 
MDA 
Acetone I Chloroform (1: 1 v/v) 
Hexane EtoAc (9: 1 v/v)) 
Hexane EtoAc (8: 2 v/v) 
Methanol 
Ext: Extracted, Uext: Unextracted 
Mean Peak 
Area Ratio 
S. D % CV 
% Recovery 
Ext Uext Ext Uext Ext Uext 
1.03 1.35 0.12 0.11 13.0 7.9 74.6 
0.97 1.35 0.05 0.11 5.3 7.9 71.7 
1.04 1.35 0.02 0.11 2.0 7.9 77.0 
1.06 1.35 0.16 0.11 15.2 7.9 78.6 
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Table 4.13 Recovery of MDMA with different eluents at pH 6 (n=3) 
Eluent 
Acetone I Chloroform (1: 1 v/v) 
Hexane EtoAc (9: 1 v/v)) 
Hexane EtoAc (8: 2 v/v) 
Methanol 
Ext: Extracted, Uext: Unextracted 
MDMA 
Mean Peak 0 
Area Ratio 
S. D I /a CV 
%Recovery 
Ext I Uext Ext I Uext I Ext I Uext I 
1.15 1 1.45 1 0.10 1 0.07 1 10.0 1 4.7 1 79.4 
1.13 1.45 0.08 0.07 7.1 4.7 77.9 
1.20 1.45 0.03 0.07 2.7 4.7 82.8 
1.07 1.45 0.04 0.07 4.0 4.7 74.1 
Table 4.14 Recovery of MDEA with different eluents at pH 6 (n=3) 
I 
Eluent 
Acetone / Chloroform (1: 1 v/v) 
Hexane EtoAc (9: 1 v/v)) 
Hexane EtoAc (8: 2 vIv) 
Methanol 
Ext: Extracted, Uext: Unextracted 
M DEA 
Mean Peak S. D % CV 
Area Ratio % Recovery 
Ext Uext Ext Uext Ext Uext 
0.12 0.15 0.02 0.01 19.9 6.08 77.6 
0.11 0.15 0.01 0.01 5.06 6.08 73.7 
0.11 0.15 0.01 0.01 5.41 6.08 76.5 
0.11 0.15 0 0.01 4.21 6.08 72.4 
4.1.1.14.2 Change in Phosphate BufferpH 
A further study was carried out to investigate how the pH of the phosphate buffer affected 
the recovery of the cannabinoids. The pH of the phosphate buffer was changed to pH 5,7 
and 8. 
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200 gI of amfetamines working standard solution and 200 gl of deuterated cannabinoids 
working standard solution all at 1 gg/ml were measured into a test tube containing 30 mg 
of blank hair. I ml of IM NaOH was added and the solution was vortex mixed. The 
solution was incubated at 95 'C for 10 minutes. After cooling to room temperature, I ml 
of 1M HCI was added to neutralize the solution. Phosphate buffer was added at either pH 
5,6,7 or 8. Each solution was ad usted to pH 5,6,7 or 8 using either 1.0 M NaOH or 1M i 
HCI and centrifuged for 20 minutes at 2000 rpm. The supernatant was transferred to a 
clean large vial for extraction as described in section 4.1.1.9. The solution was evaporated 
to dryness and derivatised as described in section 4.1.1.5.1. Each buffer was tested in 
triplicate. The deuterated working standard was added after extraction, prior to 
derivatisation. 
4.1.1.14.2.1 Results 
The recoveries of the target compounds increased with increasing pH, pH 8 giving the 
highest recoveries. The recovery of the A? -THC and A? -THC-COOH increased three and 
five times respectively from the original method using pH 6 and both showed satisfactory 
% CV reproducibility. The recoveries of amfetamines were not affected and their results 
demonstrated that pH 6 yielded the highest recoveries for all five amfetamines. The results 
are shown in Table 4.15, Table 4.16, Table 4.17, Table 4.18, Table 4.19, Table 4.20 and 
Table 4.21. 
Table 4.15 Recovery of Y-THC with varying buffer pH (n =3) 
Mean Peak Area Ratio 
PH Ext Uext 
5 0.08 1.5 
610.21 1 1.5 
0.14 1 1.5 
810.73 1 1.5 
Ext: Extracted, Uext: Unextracted 
9 A -THC 
S. D % cv 
Ext Uext Ext Uext % Recov 
0.02 0.11 29.7 7.1 5.3 
0.06 0.11 27.5 7.1 13.7 
0.05 0.11 33.7 7.1 9.0 
0.12 0.11 16.4 7.1 49.0 
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Table 4.16 Recovery of Y -THC-COOH with varying buffer pH (n =3) 
Mean Pea k Area Ratio 
PH Ext Uext 
5 0.25 2.04 
6 0.26 2.04 
7 0.42 2.04 
8 1.26 2.04 
Ext: Extracted, Uext: Unextracted 
9 A -THC-COOH 
S .D % cv 
Ext Uext Ext Uext 
0.12 0.35 48.1 17.4 
0.05 0.35 17.2 17.4 
0.17 0.35 40.1 17.4 
0.03 0.35 2.6 17.4 
Table 4.17 Recovery of AF with varying buffer pH (n = 3) 
AF 
Mean Peak Area Ratio S .D 
PH Ext Uext Ext Uext 
5 1.42 1.77 0.2 0.03 
6 1.44 1.77 0.05 0.03 
7 1.14 1.77 0.11 0.03 
8 1.05 1.77 0.12 0.03 
Ext: Extracted, Uext: Unextracted 
Table 4.18 Recovery of MA with varying buffer pH (n = 3) 
% cv 
Ext Uext 
14.2 1.8 
3.3 1.8 
9.2 1.8 
10.9 1.8 
12.2 
12.9 
20.5 
61.8 
Recovery 
80.3 
81.1 
64.1 
59.5 
MA 
Mean Peak Area Ratio S. D % cv 
PH Ext Uext Ext Uext Ext Uext % Reco) 
5 0.55 0.66 0.10 0.03 17.5 4.8 84.4 
6 0.57 0.66 0.03 0.03 5.3 4.8 87.2 
7 0.48 0.66 0.15 0.03 31.3 4.8 72.7 
8 0.49 0.66 0.09 
1 
0.03 17.8 4.8 75.1 
Ext: Extracted, Uext: Unextracted 
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Table 4.19 Recovery of MDA with varying buffer pH (n = 3) 
Mean Peak Area Ratio 
PH Ext Uext 
5 0.77 0.90 
6 0.79 0.90 
7 0.65 0.90 
8 0.58 0.90 
MDA 
S. D 
-E-x-t -TUext 
0.09 0.03 
0.08 0.03 
0.05 0.03 
0.10 0.03 
% cv 
Ext Uext 
11.3 0.03 
9.8 0.03 
8.4 0.03 
16.4 0.03 
RecoN 
Ext: Extracted, Uext: Unextracted 
Table 4.20 Recovery of IVIDMA with varying buffer pH (n = 3) 
Mean Peak Area Ratio 
PH Ext Uext 
5 0.89 1.14 
6 0.91 1.14 
7 0.80 1.14 
8 0.73 1.14 
MDMA 
S. D 
-Ex-t- T Uext 
0.13 0.05 
0.04 0.05 
0.06 0.05 
0.12 0.05 
% cv 
Ext Uext 
15.0 4.2 
3.8 4.2 
8.1 4.2 
15.8 4.2 
85.6 
87.6 
71.5 
64.8 
Recove 
Ext: Extracted, Uext: Unextracted 
Table 4.21 Recovery of MDEA with varying buffer pH (n = 3) 
Mean Peak Area Ratio 
PH Ext Uext 
5 0.11 0.13 
6 0.11 0.13 
7 0.10 0.13 
8 0.09 0.13 
MDEA 
S. D 
Ext T Uext 
0.01 0.01 
0.01 0.01 
0.01 0.01 
0.02 0.01 
% cv 
Ext Uext 
12.0 4.3 
6.9 4.3 
5.2 4.3 
18.8 4.3 
78.0 
80.1 
69.8 
64.4 
Reco) 
Ext: Extracted, Uext: Unextracted 
80.0 
84.1 
75.2 
66.5 
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4.1.1.14.3 Recovery of Cannabinoids with Phosphate BufferpH 8 and Eluent hexanel 
EtOAc (v/v) 
The recovery of the cannabinoids from hair using the best eluent and best buffer pH, 
hexane / EtOAc (8: 2 v/v) and phosphate buffer at pH 8 was investigated. The purpose of 
this experiment was to check if the modifications made an enhanced improvement to the 
method. 
200 ýtl of amfetamines working standard solution and 200 ýtl of deuterated cannabinoids 
working standard solution all at I gg/ml were measured into a test tube containing 30 mg 
of blank hair. Alkaline pre-treatment and SPE were carried out as before with the 
modifications being hexane / EtOAc as eluent and pH of buffer 8.1 ml of IM NaOH was 
added and the solution was vortex mixed. The solution was incubated at 95 T for 10 
minutes. After cooling to room temperature, I ml of 1M HCI was added to neutralize the 
solution and 2 ml of phosphate buffer, pH 8.0 was added. After adjusting with 1.0 NaOH 
to pH 8.0 and centrifuging for 20 minutes at 2000 rpm, the supernatant was transferred to a 
clean large vial for extraction as described in section 4.1.1.9. SPE was carried out as 
before, but hexane / EtOAc (8: 2 v/v) was used instead of acetone / chloroform (1: 1 v/v) as 
eluent. This was prepared in triplicate. The solution was evaporated to dryness and 
derivatised as described in section 4.1.1.5.1. The deuterated working standard was added 
after extraction, prior to derivatisation. 
The same experiment was repeated. Standards were made up as previously described and 
they were measured into a test tube without the presence of hair. The purpose of this 
experiment was to check if there was interference from hair matrices causing the decrease 
in the cannabinoids recovery. 
4.1.1.14.3.1 Results 
The results demonstrated that a low recovery of cannabinoids still persisted in the presence 
of hair. The second experiment without the presence of hair showed that the cannabinoids 
recovery was not significantly changed. Unsatisfactory % CV reproducibility was also 
shown both with and without the presence of hair. The complete results are shown in 
Table 4.22. 
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Table 4.22 Recovery of cannabinoids and amfetamines with and without presence of hair (n 
=3) 
Mean Peak 
Area Ratio S. D % Cv 
Analyte Ext Unext Ext Unext Ext Unext %Recovery Comment 
Y-THC 0.21 0.82 0.06 0.02 30.3 2.0 25.4 With Hair 
Without 
0.24 0.82 0.04 0.02 17.4 2.0 29.2 Hair 
Y -THC-COOH 0.05 1.65 0.02 0.06 45.8 3.5 3.2 With Hair 
Without 
0.16 1.65 0.05 0.06 34.1 3.5 9.5 Hair 
AF 1.78 2.24 0.11 0.03 6.0 1.4 79.3 With Hair 
Without 
1.82 2.24 0.11 0.03 6.3 1.4 81.4 Hair 
MA 0.94 1.20 0.02 0.02 2.2 1.9 78.0 With Hair 
Without 
1.01 1.20 0.08 0.02 8.2 1.9 83.9 Hair 
MDA 1.01 1.36 0.03 0.03 2.5 2.6 74.4 With Hair 
Without 
1.06 1.36 0.04 0.03 3.4 2.6 77.9 Hair 
MDMA 1.22 1.62 0.02 0.01 1.3 0.7 75.2 With Hair 
Without 
1.37 1.62 0.03 0.01 1.9 0.7 84.6 Hair 
MDEA 0.95 1.20 0.04 0.03 4.4 2.1 79.8 With Hair 
Without 
1.03 1.20 0.02 0.03 2.0 2.1 85.9 Hair 
4.1.1.14.4 Discussion and Conclusion 
The original SPE method alone without the inclusion of pre-treatment methods gave 
acceptable recoveries for all of the compounds, AF, MA, MDA, MDMA, MDEA, A? -THC 
and A? -THC-COOH. With alkaline pre-treatment and other pre-treatment methods the 
recovery of A? -THC and 
Y 
-THC-COOH decreased significantly as shown by the lack of 
detection of lower standard concentrations (5-50 ng/30mg). The combination of alkaline 
pre-treatment with SPE was not a successful combination for the cannabinoids. On the 
other hand, the amfetamines recoveries were not affected. 
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Modifications to the method were made by changing the eluent and pH. The eluent change 
showed little improvement in recovery and unsatisfactory reproducibility for A! -THC as 
shown by the high % CVs. The recovery of A? -THC-COOH was improved and also gave 
good reproducibility with Hexane / EtOAc (8: 2 v/v) as the eluent compared with the 
original eluent, acetone/chlorofonn. The recoveries of A? -THC and A! -THC-COOH were 
significantly increased with change in pH and the highest recoveries for both compounds 
were found at pH 8 with satisfactory reproducibility. However, the improvement was still 
insufficient to meet the required limits of detection. 
With the best eluent and best buffer pH, hexane / EtOAc (8: 2 v/v) and phosphate buffer at 
pH 8, the recovery of the A? -THC and A? -THC-COOH were not improved. The recovery 
of A? -THC and A? -THC-COOH with and without the presence of hair using the best eluent 
and best buffer pH did not show a significant change and their % CV reproducibility was 
also poor with and without the presence of hair. The results of this experiment 
demonstrated that the presence of hair did not affect the cannabinoids recovery. 
The low recoveries of this method meant that it was not suitable for the detection of 
cannabinoids with low concentrations in hair samples, especially for the metabolite which 
incorporates into hair at very low concentrations. The method could possibly be improved 
by using a more sensitive technique such as GC-MS-NCI or GC-MS/MS [10,134,153, 
155,156]. Further studies are needed to investigate the influence of the combination of 
alkaline pre-treatment and other pre-treatment methods with SPE. Otherwise, the analysis 
of cannabinoids must be investigated using a separate validated method. The difficulty of 
A? -THC and A? -THC-COOH determination in hair samples has also been reported by 
Moeller et al [95]. This method used fl-glucuronidase/aryl-sulfatase followed by SPE with 
acetone/dichloro form (3: 1) as eluent, PFPA/PFPOH as derivatising agents and analysis by 
GC-MS with EI detection. 
4.2 Comparison of Pretreatment Methods for Amfetamine 
Comparison of four pre-treatment methods, NaOH, fl-Glucuronidase, HCI and MeOH was 
carried out for AF only. This was because there was a difficulty in obtaining hair samples 
that were positive for all five amfetamine compounds. An authentic case sample was used 
to investigate the recovery of AF by each of the methods. This sample had previously 
been analysed by Forensic Medicine and Science, University of Glasgow and was already 
known to be positive for AF. 
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Blank and case hair samples were decontaminated using the same procedure described in 
section 4.1.1.7. For standard preparation, 30 mg samples of blank hair were weighed out 
and spiked with 5,10,25,50,100 and 200 [tl AF and 100 [d of deuterated working 
standard, both at I pg/ml to give a six point calibration curve. A blank hair sample without 
standard or internal standard and a blank hair sample with only 100 ýtl of internal standard 
were also prepared. 
The case hair sample was cut into three segments (root -3 cm, 3-6 cm. and 6- 9cm), cut 
into small pieces (1-2 mm) and 100 pl of AF deuterated working standard was added. 
Four different pre-treatment methods, described in 4.1.1.8, were used in this study. Each 
segment was divided into two portions and analysed by two different pre-treatment 
methods. It was not possible to compare all four at once because of insufficient sample. A 
calibration curve was also plotted for each pre-treatment method. The segment root -3 cm. 
was used to compare P-glucuronidase and alkaline pre-treatment. The method that gave 
the better recovery was then compared with methanol pre-treatment on segment 3-6 cm 
and the better of these two methods was compared with acid pre-treatment using segment 6 
-9 cm. SPE as described in section 4.1.1.9 was used to clean up the hair samples. The 
solution was evaporated to dryness and derivatised as described in section 4.1.1.5. L 
4.2.1 Results and Discussion 
Calibration curves by each method were plotted and were shown to give good linearity and 
R2 values similar to those shown previously in 4.1.1.10. The AF concentration results 
obtained for the case hair sample by these pre-treatment methods were calculated and they 
fell within a range of 0.21-0.53 ng / mg. The P-glucuronidase pre-treatment method gave a 
better recovery than the alkaline pre-treatment method, the methanolic pre-treatment 
method and the acidic pre-treatment method. The P-glucuronidase pre-treatment method 
was used as a reference for the other pre-treatment methods to calculate the recoveries. 
This method was assumed to give 100% recovery for AF and the recoveries obtained using 
other methods were compared to this. Alkaline pre-treatment, methanol and acid pre- 
treatment methods represented approximately 87%, 70% and 56%, respectively, compared 
with the P-glucuronidase pre-treatment method. The P-glucuronidase pre-treatment 
method was also found to be cleaner than either the alkaline or methanol extractions. The 
full scan chromatograms for blank hair samples for each pre-treatment method are shown 
in Figure 4.28, Figure 4.29, Figure 4.30 and Figure 4.31. The complete results for 
comparison are summarized in Table 4.23 and Figure 4.27. 
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P-Glucuronidase pre-treatment was selected as the method of choice for the extraction of 
AF content in hair. It was assumed that alkaline pre-treatment would give the highest 
recovery because this extraction completely dissolves the hair sample and all drugs are 
liberated from hair matrices. It has been reported that an enzyme method is suitable to 
extract all substances at neutral pH [ 166]. 
It has previously been reported [94] that four different pre-treatment procedures, methanol, 
acid (HCI 0.1 N), alkaline (NaOH I N) and enzymatic (fl-glucuronidase/arylsulfatase) pre- 
treatment were compared to determine AF, MDA and MDMA using powdered positive 
hair samples. The clean-up method was LLE with 10 ml ethyl acetate. Derivatisation was 
carried out with heptafluorobutyric anhydride/ethyl acetate (2: 1, v/v) and analysis by GC- 
MS. The results of this study demonstrated that alkaline pre-treatment gave the highest 
recoveries and direct methanol pre-treatment gave the lowest recoveries for all three 
compounds. This study concluded that the results of this comparison study are not enough 
to detennine which extraction method is best. It was reported that factors such as the 
precision and practicality of each method should also be taken into account, when 
extraction comparison studies are carried out [70]. 
In another study, three pre-treatment methods were compared to extract amfetarnines from 
hair samples. These were sodium hydroxide, methanol / HCl and methanol / 
trifluoroacetic acid. The highest recoveries of AF, MA, MDA, MDMA and MDEA from 
hair were found by acid pre-treatment with SPE extraction. In contrast, alkaline pre- 
treatment was found to give the best recoveries when LLE was used before SPE [92]. 
Acid pre-treatment and alkaline pre-treatment followed with ether extraction were 
compared in another study involving monkey hair. This showed that there were no 
significant differences in recovery between these extractions for AF and MA, but the acidic 
method was found to be a cleaner extract and gave lower standard deviations [97]. 
The results of these studies differ with the findings in this investigation which showed that 
the fl-glucuronidase method gave the highest recovery of AF. Although, alkaline pre- 
treatment has the ability to liberate the drugs from the hair sample it requires extensive 
clean up procedures to eliminate hair matrix substances which can cause interference with 
the analysis. This has been highlighted in the previously mentioned article where both 
LLE and SPE were used following alkaline pre-treatment [92]. Obtaining good recoveries 
with alkaline pre-treatment is dependent on having good purification of the hair digest to 
eliminate more interfering substances. It would appear that the combination of a pre- 
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treatment step and a particular clean-up method may significantly affect the recovery. For 
instance, alkaline pre-treatment with LLE may produce the highest recovery compared 
with other pre-treatment methods with the same LLE. However, another type of pre- 
treatment method may be better with SPE than the alkaline pre-treatment with the same 
SPE method [94]. 
Other factors that need to be considered when choosing a method are the cost and time of 
sample preparation. Extensive clean-up procedures may significantly increase both of 
these factors. It was reported that there are important considerations which should be kept 
in mind when selecting the pre-treatment procedures such as type of analyte and its 
stability, distribution ratio between analyte and its metabolites and finally, subsequent 
analysis (qualitative or quantitative) [ 167]. 
Table 4.23 The concentration of AF measured in different segments of the authentic hair 
sample 
Methods 
Concentration 
Seqment I Percentage 
Alkaline 0.46 Root -3 cm 87% 
Enzymatic 0.53 Root -3 cm 100% 
Methanol 0.21 3-6 cm 70% 
Enzymatic 0.3 3-6 cm 100% 
Acid 0.26 6 -9 cm 56% 
Enzymatic 0.46 6 -9 cm 100% 
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Figure 4.27 The concentration of AF in different segments of the authentic hair sample 
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Figure 4.28 Full Scan Chromatogram of blank hair sample after enzymatic pro-treatment 
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Figure 4.29 Full Scan Chromatogram of blank hair sample after acid pre-treatment 
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Figure 4.30 Full Scan Chromatogram of hair blank sample after alkaline pre-treatment 
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Figure 4.31 Full Scan Chromatogram of blank hair sample after methanolic pre-tretment 
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4.3 Method validation 
In accordance with the results of the comparative study in section 4.2, the best recovery for 
AF was obtained by the fl-glucuronidase pre-treatment method. This method as described 
in 4.1.1.8 was used and validated for amfetamines in hair. 
Hair samples were decontaminated using the same procedure described in section 4.1.1.7, 
the solutions were extracted using the SPE method as described in section 4.1.1.9 and the 
solution was evaporated to dryness and derivatised as described in section 4.1.1.5.1. 
4.3.1 Linearity 
Linearity was demonstrated by plotting the calibration curves of five amfetamines. 
Standards were prepared by weighing 30 mg of blank hair into a test tube and spiking with 
5,10,25,50,100 and 200 pl of aI pg/ml working standard solution containing AF, MA, 
MDA, MDMA and MDEA. 100 pl of deuterated internal standard at 1 Pg/ml was added to 
every standard to give a six point calibration curve. A blank hair sample without standard 
or internal standard and a blank hair sample with only 100 pI of internal standard were also 
prepared. Calibration curves were plotted using concentration against PAR (drug peak 
area / internal standard peak area) of each amfetamine. The results are presented in Table 
4.24, Table 4.25 and Figure 4.32. 
4.3.2 Recovety 
The recoveries were determined and calculated at low, medium and high concentrations for 
each of the five amfetamines, by taking the mean PAR of extracted samples divided by the 
mean PAR of the unextracted standards at the equivalent concentration and multiplying by 
100. Spiked hair samples (30 mg) were prepared in five replicates at three different 
concentrations (10,50 and 200 pl of a l[tg/mI standard). Unextracted standards were 
prepared at the same time as spiked hair samples and kept in the fridge while the extraction 
was carried out. Deuterated internal standards (100 pI of a1 [tg/ml standard) were added to 
extracts and unextracted standards after the extraction. The results are presented in Table 
4.26. 
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4.3.3 Intra-day and Inter-day Precision 
4.3.3.1 Intra-day precision between extracts 
The intra-day precision between extracts was carried out in five replicates. Spiked hair 
samples (30 mg) were prepared on the same day at three different concentrations (10,50 
and 200 ýtl of aI ýLg/ml standard) in the presence of deuterated internal standard (100 pl of 
a1 [tg/ml standard). The results are presented in Table 4.27. 
4.3.3.2 Intra-day precision between injections 
The intra-day precision between injections was carried out by injecting the same standard 
five times. Spiked hair samples (30 mg) were at three different concentrations (10,50 and 
200 ýtl of a Iýtg/ml standard) in the presence of deuterated internal standard (100 ýtl of a 
I ýtg/rnl standard. The results are presented in Table 4.28. 
4.3.4 Inter-day Precision 
Inter-day precision was determined by using spiked hair samples (30 mg) at three different 
concentrations (10,50 and 200 ýtl of a 1ýtg/ml standard) in the presence of deuterated 
internal standard (100 [tl of a l[tg/ml standard) over a period of five days. The results are 
presented in Table 4.29. 
4.3.5 Limits of Quantitation and Detection 
The limits of quantitation (LOQ) and detection (LOD) were calculated from the intercept 
and the standard error of the regression line. The equations used for calculation of LOQ 
and LOD are shown in the equations 1 and 2 for LOQ and the equations 3 and 4 for LOD, 
where yB is intercept, SB is the standard error of the regression line and m is the gradient. 
The calibration curves of all five arnfetamines were plotted, by spiking blank hair samples 
(30 mg) with amfetarnine standards to obtain concentrations of 0.5,0.75,2,5,10 and 25 
ng/30 mg of hair and adding 100 ýLl of a 1ýtg/ml deuterated internal standard. A blank hair 
sample without standard or internal standard and a blank hair sample with only 100 ýtl of 
internal standard were also prepared and extracted. The limit of detection is defined as the 
intercept plus three standard errors of the regression line and the limit of quantitation is 
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defined as intercept plus five standard errors of the the regression line [168]. The limits of 
detection and quantitation for all arnfetamines are presented in Table 4.30. 
YLOQ = yB+5 SB Equation 1 
L. O. Q = 
(YLOQ 
- YB) Equation 2 
m 
YLOD ý YB+3 SB Equation 3 
L. O. D = 
(YLOD 
- YB) Equation 4 
m 
Table 4.24 Calibration concentration and peak area ratio for extracted amfetamines 
Concentration 
(ng/30mg) 
AF/AF-ds 
1901194 
MA/MA-ds 
204/208 
MDA/MDA-ds 
3251330 
MDMA/MDMA-ds 
339/344 
MDEAIMDEA-d5 
218/223 
5 0.07 0.04 0.09 0.07 0.01 
10 0.15 0.08 0.16 0.15 0.02 
25 0.34 0.19 0.34 0.29 0.05 
50 0.65 0.4 0.67 0.68 0.09 
100 1.22 0.75 1.21 1.25 0.18 
200 2.45 1.48 2.47 2.49 0.35 
Table 4.25 Linear regression values 
Analyt 
AF 
MA 
MDA 
MDMA 
MDEA 
R2 
1.000 
0.996 
0.999 
0.999 
1.000 
Interce 
0.0267 
0.0109 
0.0360 
0.0164 
0.0037 
0.0121 
0.0074 
0.0121 
0.0124 
0.0017 
Slo 
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Figure 4.32 Amfetamines Calibration curves (AF, MA, MDA, MDMA and MDEA, 0 to 200 ng) 
Table 4.26 Recovery results for the extracted Amfetamines from hair (n=5) 
Concentration Mean Peak Area Ratio S. D % Cv % 
Analyte (ng) Ext Unext Ext I Unext Ext Unext Recove! y 
AF 10 0.09 0.11 0.00 0.01 4.82 7.07 84.2 
50 0.43 0.57 0.02 0.02 4.65 3.08 76.0 
200 1.65 2.35 0.01 0.08 0.86 3.56 71.4 
MA 10 0.08 0.11 0.00 0.00 4.36 4.31 77.7 
50 0.39 0.53 0.02 0.02 5.6 3.55 74.2 
200 1.58 1.80 0.11 0.10 7.27 5.55 87.7 
MDA 10 0.11 0.13 0.00 0.01 4.23 4.69 79.6 
50 0.49 0.65 0.01 0.02 2.42 3.12 75.7 
200 2.12 2.74 0.10 0.09 4.82 3.44 77.3 
MDMA 10 0.01 0.18 0.01 0.01 5.75 5.77 76.0 
50 0.66 0.87 0.01 0.03 2.01 3.2 76.2 
200 2.89 3.72 0.14 0.15 4.83 3.94 77.6 
MDEA 10 0.01 0.02 0.00 0.00 1.33 6.77 82.6 
50 0.07 0.08 0.00 0.00 5.38 3.1 85.2 
200 0.28 0.31 0.02 0.01 6.30 3.68 88.4 
Diagnostic Use of Hair Analysisfor the Detection of Misuse ofAmfetamines and Cannabinoids 
0 50 100 150 200 250 
Concentration (ng) 
Chapter Four: Analysis of Amfetamines and Cannabinoids Page 102 
Table 4.27 Intra-day Precision (between extraction, n=5) 
knalyte 
Concentration 
ng / 30mg 
Calculated Concentration 
Mean ng / 30mg S. D C. V 
AF 10 11.41 0.30 2.61 
50 48.34 2.13 4.40 
200 200.10 15.52 7.76 
MA 10 10.32 0.71 6.86 
50 49.53 2.88 5.81 
200 207.28 19.88 9.60 
MDA 10 10.53 0.50 4.74 
50 48.53 2.53 5.34 
200 199.97 11.66 5.83 
MDMA 10 10.93 1.04 9.52 
50 46.74 3.87 8.29 
200 200.00 9.04 4.52 
MDEA 10 13.28 0.53 3.97 
50 49.00 2.08 4.24 
200 196.62 10.91 5.55 
Table 4.28 Intra-day Precision (between injection, n=5) 
Anall 
AF 
MA 
MDA 
MDMA 
MDEA 
Concentration 
na/ 30ma 
10 
50 
200 
10 
50 
200 
10 
50 
200 
10 
50 
200 
10 
50 
200 
Calculated Concentration 
Mean na / 30ma 
10.75 
49.12 
200.88 
9.04 
50.77 
199.52 
12.46 
46.74 
201.55 
10.07 
49.92 
199.74 
14.34 
49.14 
203.14 
S. D 
0.75 
0.40 
2.37 
0.34 
0.46 
2.32 
0.57 
2.61 
14.88 
0.58 
3.92 
2.71 
0.37 
0.41 
1.57 
C. V 
7.01 
0.81 
1.18 
3.75 
0.91 
1.16 
4.57 
5.58 
7.38 
5.78 
7.85 
1.36 
2.56 
0.84 
0.77 
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Table 4.29 Inter-day Precision (n=5) 
Analyte 
Concentration 
ng 130mg 
Calculated Concentration 
Mean ng 130mg S. D C. V 
AF 10 11.27 1.76 15.6 
50 47.36 4.29 9.0 
200 201.95 2.01 1.0 
MA 10 11.09 2.06 18.5 
50 47.80 5.22 10.9 
200 203.47 5.24 2.5 
IVIDA 10 11.07 2.13 19.2 
50 49.48 4.43 8.9 
200 202.45 3.39 1.6 
IVIDIVIA 10 11.34 2.09 18.4 
50 48.73 3.31 6.8 
200 202.12 2.34 1.1 
IVIDEA 10 10.90 2.02 18.5 
50 46.28 3.32 7.1 
200 202.31 1.97 0.9 
Ext: Extracted, Uext: Unextracted 
Table 4.30 Limit of Quantitation and Detection 
AF MA MDA MDMA MDEA 
(ng/30mg) (ng/30mg) (ng/30mg) (ng/30mg) (ng/30mg) 
LOD 2.58 0.70 2.19 2.33 1.36 
LOQ 4.30 1.17 3.89 3.65 2.25 
4.3.6 Results and Conclusion 
The method validation was carried out for linearity, recoveries, intra and inter-day 
precision, limit of quantitation (LOQ) and limit of detection (LOD) for all amfetamines 
compounds. Linearity was obtained from 5 to 200 ng/30mg of hair with correlation 
coefficients (112) ranging from 0.999-1.000 for all amfetamines. The recovery for all five 
amfetamines was higher than 71%. Coefficients of variation for the intra-day precision 
between extracts and between injections were all less than 10 % at each concentration for 
all five amfetamine compounds. Coefficients of variation for the inter-day precision were 
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all less than 15 % at each concentration for all five amfetarnine compounds. The limits of 
detection and quantitation for all five amfetarnines were between 0.7 to 2.58 ng/30mg and 
1.17 to 4.3 ng/30mg, respectively. The method validation results showed good validation 
data for all five amfetamines and indicated that this method is adequate for the purpose of 
the amfetamines analysis in hair with satisfactory sensitivity. Consequently, this method 
was applied to 22 case hair samples to measure the concentration of arnfetamines (Chapter 
6). 
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5 Stability of Amfetamine in Hair Samples 
5.1 Introduction 
The stability of drugs in biological fluids may be affected by different factors such as 
temperature, storage time, drug concentration, sample, pH, the type of biological fluid, the 
use of preservatives and the method of storage. All of these can lead to a significant 
change in the analyte concentration within the specimen and can lead to misinterpretation 
of quantitative results [169]. Consequently, the forensic toxicologist must consider the 
limited stability of specimens to give the proper interpretation of analytical results. For 
instance chemical degradation, ongoing enzymatic metabolism and redistribution happens 
in postmortem specimens between the death and the sampling of matrices [80]. It has been 
reported that all drug concentrations can change in postmortem specimens and that the 
change varies between drugs [125]. 
The stability of MDA, MDMA and MDEA in pooled serum, whole blood, water and urine 
samples whilst stored at different temperatures (-20,4 or 20 'Q in the dark over a period 
of 21 weeks has been investigated. It was reported that there was no degradation. 
Therefore, MDA, MDMA or MDEA samples stored for several weeks (13 weeks for 
whole blood and Z!: 21 weeks for the other matrices, water, serum and urine) are appropriate 
to analyse. Severe matrix degradation was found for whole blood and serum stored at 
room temperature which could lead to undetectable concentrations of the drugs, 
particularly where the initial concentrations are low [80]. 
The stability of drugs (methoxyphenamine, as model compound for methamfetamine) in 
hair samples was described. Drug levels in hair were measured in a living subject over a 
period of 6 months. The results obtained from this study revealed that the drug decreased 
about 50% after 5-6 months. This decrease is likely to be a result of drug being removed 
from hair through normal washing and possibly the decomposition of some of the drug 
with time [ 170]. 
The stability of opiates in hair was investigated after cosmetic treatment (bleaching and 
permanent waving) of hair spiked with opiates and authentic hair samples known to be 
positive for opiates. The results showed a decrease in the concentration of spiked hair 
samples that ranged from 82 % to 98 % after bleaching and ranged from 70 % to 80 % 
after permanent waving. The drug concentration also decreased for authentic hair samples, 
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but was not as significant. Exposure of human hair scalp to sunlight and cosmetic 
treatment was also shown to cause morphological alterations in the hair fibres affecting the 
drug concentrations [ 17 1 ]. 
It has been reported that the opiates were significantly decreased or even lost when hair 
samples were exposed to unfavourable environmental conditions such as water and soil for 
various time intervals [172]. 
Although a number of analytical methods have been reported for the analysis of AF in hair 
samples as mentioned previously in section 3.1.6, none of these methods have reported on 
the stability of AF in hair in cases of drowning through immersion in either sea or fresh 
water. For this study, the effect of sea water and fresh water on the concentration of AF in 
hair specimens was investigated. 
5.2 Alm 
The aim of this study was to assess the validity of analysing hair samples for the presence 
of AF in victims of drowning. 
5.3 Experimental 
5.3.1 Hair and Water Collection 
AF positive hair samples were collected from volunteers, with known AF drug abuse 
history. This was assessed using medical files. In many of these cases urine samples had 
been previously analysed by the laboratory at the Alarnal Medical Complex in Riyadh 
prior to subjects entering rehabilitation programs. The majority of these samples were 
found to be positive for AF. Hair was obtained by cutting from the area at the back of the 
head (posterior vertex) and as close to the scalp as possible. Once collected, a hair sample 
was placed in aluminium foil, with the scalp end clearly identified, sealed in a paper 
envelope and stored at room temperature until use. 
The fresh and sea water were obtained from Loch Lomond and from the River Clyde 
Estuary, Gourock near Glasgow in Scotland, respectively. 
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5.3.2 Stability of Amfetamine in Hair Samples Submerged in Fresh 
Water and Sea Water 
5.3.2.1 Initial study for Arnfetarnine Stability 
A preliminary experiment was carried out to assess the stability of AF in hair samples 
which had been submerged in fresh and sea water for different periods of time. 
In order to prepare hair standards, 30 mg of blank hair samples were weighed out and 
spiked with 5,10,25,50,100 and 200 pl of AF and 100 pl of deuteratcd working standard, 
both at I gg/ml to give a six point calibration curve. A blank hair sarnPle without standard 
or internal standard and a blank hair sample with only 100 Itl of internal standard at I 
pg/ml were also prepared and extracted. 
A hair positive specimen was cut to give 0-3 cm length and this was separated into 7 
portions. One of these portions was stored as an original specimen and 3 portions were 
immersed in 5 ml of sea water and the other 3 portions were immersed in 5 ml of fresh 
water for 1 day, I week or 2 weeks at 5 T. Hair samples were analysed using the 
validated method described in section 4.3. 
5.3.2.1.1 Initial Study Results 
All wash fraction results were negative for AF. A calibration curve was plotted for AF and 
was shown to give good linearity and W values similar to that shown previously in section 
4.1.1.10. 
The preliminary results obtained in this study showed that the AF hair concentration 
significantly decreased with the length of time in sea water, while the AF hair 
concentrations showed no obvious change in fresh water. The decrease of hair AF 
concentration in sea water was approximately 40% after one day, 69% after one week and 
84% after two weeks. The complete results for the AF concentrations found in the hair 
samples are summarised in Figure S. 1 and Table 5.1. 
The preliminary data from this study showed that there was an effect on the concentration 
of AF in hair when submerged in different types of water (fresh and sea). These results led 
to a further investigation to assess the stability of AF in hair samples submerged in these 
types of water. 
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Figure 5.1 Effect of sea and fresh water on AF concentration 
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Table 5.1 Concentration of AF in hair after immersion in sea and fresh water (ng/mg) 
Incubation Time I Sea Water i Fresh Water 
Original 51.3 51.3 
One Day 30.8 46.9 
One Week 15.8 46.7 
Two Weeks 8.1 46.6 
5.3.2.2 Further Investigation into the Stability of Amfetamine in Hair Samples 
Hair standards were prepared as in section 5.3.2.1. Ten hair samples from known AF users 
were collected and used to assess the stability of AF in hair samples which had been 
submerged in fresh or sea water for a period time. Fresh water and sea water were 
analysed for AF using the 0-glucuronidase validated method described in section 4.3. This 
was to ensure that the water samples were negative and that any possibility of 
contamination from the water could be excluded. 
Hair positive specimens were cut to give 0-3 cm length. Six of these specimens were 
separated into 8 portions each. One of these portions was stored as an original specimen 
and 7 portions were immersed in 5 ml of sea water for 1,2 days, 1,2,3,4 or 8 weeks at 5 
T. The other four specimens were separated into 5 portions, one of these portions was 
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stored as an original specimen and 4 were immersed in 5 ml of fresh water for 1,2,4 or 8 
weeks at 5 'C. Each portion was removed from the water after the period of immersion 
and dried overnight at room temperature. Hair samples were analysed using the validated 
method described in section 4.3. 
The fresh and sea water samples which were used to immerse the hair for a period of eight 
weeks were analysed following immersion to investigate the AF content. The cation and 
anion content, pH and conductivity of the two water types were also measured, in 
collaboration with the Department of Environmental Chemistry at Glasgow University. 
Calcium (Ca2+), Magnesium (Mg2+), Sodium (Na+), Potassium (W-), Chloride(Cl-) and 
Sulphate (SO 4 2-), conductivity, pH were measured using an Atomic Absorption 
spectrophotometer, Flame Photometer, Ion Chromatography, Conductivity Meter and pH 
Meter, respectively. 
5.3.2.2.1 Result and Discussion 
A calibration curve was plotted for AF and was shown to give good linearity and R2 values 
similar to that shown previously in section 4.1.1.10. For hair samples incubated in salt 
water, DCM wash fraction 3 was found to be positive in 24 out of 48 segments. DCM 
wash fraction 4 was found to be negative for all segments. For hair samples incubated in 
fresh water, only 2 out of 21 segments were found to be positive. These were very low 
positives, so these segments did not require further washing. Washing the hair in salt water 
would appear to remove some of the drug incorporated through use. It is possible that 
soaking in salt water may increase the porosity of the cuticle compared with soaking in 
fresh water. The wash fraction results are listed in Table 5.2 and Table 5.3 
Fresh water and sea water samples analysed prior to the immersion of hair were 
detennined to be negative for AF. 
The initial concentrations of the hair samples investigated ranged from 0.17 to 57.69 
ng/mg of hair. Hair samples that were submerged in sea water showed a significant 
decrease of AF concentration with time compared with hair samples that were submerged 
in fresh water. The decrease in hair AF concentration after one day in sea water ranged 
from 0.1-85% and after eight weeks ranged from 88-97%. In fresh water, after one week 
the concentration was found to decrease by 9-17% and after eight weeks by 16-60%. The 
complete results for the AF concentrations found in the hair samples are given in Table 5.4 
and Table 5.5. 
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Figure 5.2 and Figure 5.3 show the general decrease in hair AF concentration with time for 
immersion in sea and fresh water respectively. In Figure 5.2 the log concentration was 
plotted against time. 
The sea and fresh water samples which were used to immerse the hair for a period of eight 
weeks were found to be positive for the unchanged drug. The original total amount of drug 
in the hair sample (ng) was calculated by multiplying the original concentration in hair 
(ng/mg) by the weight of the hair used. The complete results are given in Table 5.6 and 
Table 5.7. These Tables show the amount of drug washed out as a percentage of the 
amount of drug found in the water sample compared to the amount extracted from hair. In 
all six sea water cases and in two out of four fresh water cases this % was greater than 100 
%. This would tend to show that the true recovery of AF from hair is much lower than the 
recovery of AF from spiked hair samples. 
The pH measurements of sea and fresh water were 8.1 and 7.0 respectively. The 
conductivity of sea and fresh water samples were 615 and 0.94 mS respectively. The 
cation and anion content of the two water types are given in Table 5.8. 
The results demonstrated a faster decrease of AF concentration in sea water than in fresh 
water. A possible explanation could be the displacement effect of metal ions in the water 
(especially cations) with AF. For example, keratin and melanin present in hair have 
potential binding sites for binding drugs and metals [173], such as, inorganic metal cations, 
neutral organic compounds, and organic cations [37]. Binding with these substances can 
be selective [35] and the affinity of the interaction can be varied depending on the 
substance [38]. The exact interaction of melanin with these substances is still unknown 
[174]. 
The presence of cystine in human hair, which represents approximately 14% of the 
structure is largely responsible for the high affinity of hair for metals. The metals found in 
hair are bound either to sulphur atoms in cystine or to sulphydryl groups present in other 
amino acids. 
Melanins are polyanionic polymers containing negatively charged carboxyl groups and 
serniquinones at physiological pH. Therefore cations can bind with melanin by ionic 
interaction. Moreover, organic amines and metal ions are positively charged at 
physiological pH and bind with melanin by electrostatic forces between their cationic 
groups and the negative charges in the melanin polymer. Van der waal's attractions also 
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enhance the ionic binding. Also, uncharged metals such as mercury, may also bind to the 
hydrophobic core of the melanin in the hair [175] 
The competition between drugs to melanin binding sites has been reported. The binding of 
desipramine to melanin was reduced in the presence of haloperidol. This study showed 
that these drugs may use similar binding sites in melanin and are competitive for these. 
[176] 
The binding of Mg(II), Ca(II), Zn(II), Cu(II) and Fe(III) to Ethylenediaminetetraacetic acid 
(EDTA)-washed melanin, obtained from cuttlefish, was examined by enriching melanin 
with these metal ion solutions at room temperature overnight. It was reported that 
eumelanin possesses three types of functional groups which can act as binding sites to 
metal cations, carboxylic acid, hydroxyl and amine groups. It was concluded that Mg(II), 
Ca(II), Zn(II) bind to carboxylic acid groups, Cu(II) binds to hydroxyl(OH) groups and 
Fe(III) binds to hydroxyl or amine groups. Binding of metal cations with carboxylic acid 
will replace Na+ which is the bound metal cation in (EDTA)-washed melanin, while 
binding to hydroxyl and amine groups replaces the proton (H), consequently, the pH will 
changed by releasing protons in solutions [177] 
The determination of the relative melanin-affinity of metal ions was assessed by the ability 
of the metal ions to compete with paraquat for binding to melanin. It was reported that the 
affinity of the alkali metals and alkaline earth metals was Cs+>Rb+>W>Na+>Li+ and 
Ba2+>Sr2+>Ca2+>Mg2+ respectively. The presence of the metal ions will decrease and 
inhibit of the parquet binding to melanin [178]. 
Melanin therefore may behave as a weak cationic exchange polymer and may bind with 
cationic drugs such as AF both ionically and covalently [179,180]. Amfetamine is a polar 
drug and binds with polar functional groups such as hydroxyl, carboxylic acid, and amino 
goups in melanin [IS I). 
It has been reported that while metal ions such as Na+, Ca2+, Ký may compete for binding 
sites in melanin and inhibit cationic drugs from binding with melanin, especially when 
competing for the same binding sites, anions did not effect this binding [182]. 
Consequently, the high concentration of cations in the sea water may explain the increased 
rate of removal of AF from hair when compared to fresh water. 
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The sea and fresh water samples used to incubate the hair were extracted by SPE and 
analyzed after eight weeks of incubation. The analyses showed the presence of AF in all 
samples at reducing concentrations with time due to the removal of the AF from hair to 
water. The unchanged drug was found in the water samples. Interestingly, more drug was 
recovered in the water than expected indicating that the analytical method used to extract 
AF from the real hair sample has a much lower recovery than indicated by the use of 
spiked standards. 
It has been shown that the interpretation of drugs found in hair samples obtained from 
victims of drowning require careful interpretation. Sea water has the potential to cause the 
complete loss of drug from hair with increased time, while, fresh water may cause partial 
or possible complete loss with increased time. 
6 
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Table 5.2 Concentration of AF in wash fractions for the samples submerged in sea water 
Sample I Incubation 
Sea Water, Hair 05 
Sea Water, Hair 08 
Sea Water, Hair 10 
Sea Water, Hair 12 
Sea Water, Hair 16 
Sea Water, Hair 17 
time 
Original 
One day 
Two day 
One week 
Two week 
Three week 
Four week 
Eight week 
Original 
One day 
Two day 
One week 
Two week 
Three week 
Four week 
Eight week 
Original 
One day 
Two day 
One week 
Two week 
Three week 
Four week 
Eight week 
Original 
One day 
Two day 
One week 
Two week 
Three week 
Four week 
Eight week 
Original 
One day 
Two day 
One week 
Two week 
Three week 
Four week 
Eight week 
Original 
One day 
Two day 
One week 
Two week 
Three week 
Four week 
Eight week 
AF Concentration in Wash Fractions (ng/mg) 
DCM Wash Fraction I DCM Wash Fraction 4 
14.61 0.00 
1.80 0.00 
0.57 0.00 
0.34 0.00 
0.07 0.00 
0.43 0.00 
0.25 0.00 
0.00 0.00 
0.43 0.00 
0.03 0.00 
0.00 0.00 
0.00 0.00 
0.00 0.00 
0.00 0.00 
0.00 0.00 
0.00 0.00 
0.53 0.00 
0.96 0.00 
0.80 0.00 
0.00 0.00 
0.00 0.00 
0.00 0.00 
0.00 0.00 
0.00 0.00 
0.00 0.00 
0.40 0.00 
0.00 0.00 
0.00 0.00 
0.00 0.00 
0.00 0.00 
0.00 0.00 
0.00 0.00 
6.50 0.00 
0.00 0.00 
1.12 0.00 
0.00 0.00 
0.15 0.00 
0.26 0.00 
0.11 0.00 
0.00 0.00 
31.99 0.00 
19.35 0.00 
0.22 0.00 
0.00 0.00 
7.09 0.00 
0.47 0.00 
1.26 0.00 
0.00 0.00 
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Table 5.3 Concentration of AF in wash fraction for the samples submerged in fresh water 
Sample No. 
Fresh Water, Hair 04 
Fresh Water, Hair 09 
Fresh Water, Hair 11 
Fresh Water, Hair 15 
Incubation 
time 
Original 
One week 
Two week 
Four week 
Eight week 
Original 
One week 
Two week 
Four week 
Eight week 
Original 
One week 
Two week 
Four week 
Eight week 
Original 
One week 
Two week 
Four week 
Eight week 
AF Cnneentration in Wash Fractions (n 
DCM Wash Fraction 3 
0.00 
0.00 
0.00 
0.00 
0.00 
0.02 
0.00 
0.00 
0.00 
0.00 
0.04 
0.00 
0.00 
0.00 
0.00 
0.00 
0.00 
0.00 
0.00 
0.00 
Table 5.4 Concentration of AF in hair after immersion in sea water (ng/mg) 
Sea Water Hair 05 1 Hair 08 Hair 10 Hair 12 Hair 16 Hair 17 
Original 16.52 2.08 1.69 0.17 12.38 57.69 
One Day 4.68 0.81 0.66 0.17 3.93 8.57 
Two Days 2.72 0.63 0.57 0.17 1.25 8.32 
One Week 2.17 0.37 0.34 0.16 1.19 5.34 
Two Weeks 1.09 0.32 0.22 0.10 0.90 3.18 
Three Weeks 0.84 0.31 0.18 0.09 0.85 2.55 
Four Weeks 0.79 0.22 0.16 0.09 0.62 2.18 
Eight Weeks 0.65 0.13 0.10 0.02 0.49 1.40 
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Figure 5.2 Effect of sea water immersion on AF concentration in hair 
Table 5.5 Concentration of AF in hair after immersion in fresh water (ng/mg) 
Fresh Water Hair 04 Hair 09 Hair II 
Original 2.49 11.12 4.73 
One Week 2.25 9.78 4.09 
Two Weeks 1.90 9.46 3.95 
Four Weeks 1.85 9.38 3.24 
Eight Weeks 1.78 9.29 1.86 
Amfetamine 
14 
E 12 
lo 
a 
0-" 
Orginal One week Two weeks Four Weeks Eight Weeks 
Figure 5.3 Effect of fresh water immersion on AF concentration in hair 
Hair 15 
12.12 
10.05 
8.89 
8.29 
6.41 
Hair 04 
Hair 09 
Hair 11 
Hair 15 
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Table 5.6 AF concentration in hair and sea water after eight weeks 
Sample 
No. 
Original 
concentration in 
hair, ng/mg 
Original total 
amount in hair 
Sample, ng 
Incubation water 
concentration, 
ng/water sample 
% Washed 
out 
Hair 05 16.52 256.23 479.84 187.3 
Hair 08 2.08 30.91 110.56 357.7 
Hair 10 1.69 43.60 70.15 160.9 
Hair 12 0.17 2.40 3.58 149.2 
Hair 16 12.38 168.49 336.69 199.8 
Hair 17 57.7 777.8 992.76 127.6 
Table 5.7 AF concentration in hair and fresh water after eight weeks 
Original 
Sample concentration 
No. in hair, ng/m 
Hair 04 2.49 
Hair 09 11.12 
Hair 11 4.73 
Hair 15 12.12 
Original total 
amount in hair 
Sample, ng 
37.92 
241.86 
74.88 
161.2 
Table 5.8 Physical properties of water 
Incubation water 
concentration, % Washed 
ng/water sample out 
47.28 124.7 
275.81 114.0 
67.8 90.5 
46.56 28.0 
Cation Concentration (mg/L) Anion Concentration (mg/L) 
Metal ions Sea Water Fresh water Sea Water Fresh water 
Sodium, Na+ 9,800 6.2 
Calcium, Ca 2+ 313 3.7 
Potassium, K+ 450 0.4 - 
Magnesium, Mg 2+ 940 0.9 
Chloride, Cl- 18,625 7.8 
Sulphate, S04 2- 715 0.8 
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6 Case studies 
6.1 Introduction 
Hair samples were collected from volunteers with a known history of Fenethylline (AF 
precursor) abuse and were subjects in rehabilitation programs at Alamal Medical Complex 
in Riyadh, Saudi Arabia. Urine samples previously received from these volunteers had 
been analysed by the laboratory at the Alarnal Medical Complex in Riyadh and most of 
these were found to be positive for AF. 
Hair samples were obtained by cutting from the area at the back of the head and as close to 
the scalp as possible at the posterior vertex region of the head. Once collected, these were 
stored at room temperature in aluminium foil and sealed in paper envelopes until use. 15 
hair samples were obtained from the Alamal Medical Complex. One other case hair 
sample collected from a living individual within the UK was received by Forensic 
Medicine and Science. The hair samples were cut to give 0-3 cm lengths. 2 out of the 16 
hair samples were cut to give a further three and six segments, each 3 cm long. 
Case sample details were collected for each of the volunteers. These included sex and age 
of the individual, hair colour, information regarding drug use, date of admission to 
rehabilitation programme and the date of hair collection. These results are tabulated in 
Table 6.1. 
Postmortem hair samples were obtained from the Department of Forensic Medicine and 
Science, University of Glasgow. These hair samples were pulled from the posterior vertex 
region of the scalp. Once collected, these were stored at room temperature in aluminium 
foil and sealed in paper envelopes until use. Hair case samples were selected depending on 
the results of the post-mortem blood sample received from the same case. If the blood was 
positive for AF or related compounds and a hair sample was available then these hair 
samples were selected. 6 case hair samples were obtained in these types of cases. The hair 
samples were cut to give 0-3 cm. lengths. 
For these cases, sex and age of the individual, hair colour, information regarding drug use 
and cause of death were recorded where available from police and pathology reports. 
These are shown in Table 6.2. 
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The validated method as described previously in section 4.3 was applied to the 22 case hair 
samples. 
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6.2 Results and Discussion 
Thirteen urine case sample results which were screened by the Alamal Medical Complex 
were positive for amfetamine. In each case, chronic amfetamine abuse was confirmed by 
the result of the hair analysis, where amfetamine was found in 0-3 cm of all hair samples 
and also in each segment of hair samples labelled as Hair07 and Hair18 in Table 6.1. All 
other amfetamines (MA, MDA, MDMA and MDEA) gave negative results. For all case 
samples, these results showed good qualitative correlation between self-reported use, urine 
result at admission and hair result for AF. These hair sample results were only positive for 
AF which is likely to have come from the use of the AF precursor, fenethylline, where 
27% of the fenethylline dose is excreted as racemic amfetamine [79]. In this study, self- 
report showed good agreement with hair findings. The concentration of AF in hair ranged 
from 0.15 - 57.69 ng/mg. The results are summarized in Table 6.3. These values 
correspond with other studies. One study reported AF hair concentrations in the hair of 40 
volunteer subjects ranging from 0.01-4.46 ng/mg. These individuals were on rehabilitation 
programs and were known drug users [65]. In another study the concentration of AF in 
hair ranged from 0.74-1.02 ng/mg in healthy young amfetamines users [87]. 
It was difficult in this study to try and directly correlate the dose with the amount of AF 
found in the hair because the dose of fenethylline in these cases was unknown. The self- 
reports of the volunteers showed that a variable number of fenethylline tablets were used. 
The exact dose of fenethylline in these cases was unknown i. e. tablets can be of varying 
doses. An attempt was made to find if there was any correlation between self-reported use 
and the amount of amfetamine found in hair. For this purpose, the dose of each tablet was 
assumed to be the same. The case hair samples were categorised into three different 
groups according to the number of fenethylline tablets used. These were low (1-2 tablets), 
medium (3-5 tablets) and high (> 5 tablets). Self-reports (amount of tablets) and 
concentration of AF in hair was compared. These results showed that there was overlap 
between the three levels. The lowest and highest levels found in hair fell into the medium 
category and not into the low and high categories respectively. This may be explained by 
by the varying dose in tablets and the inaccuracy of self-report data. These results are 
summarised in Table 6.5. 
The effect of hair colour on the incorporation of AF into hair was eliminated in this study, 
because the majority of hair samples (15 out of 16) were the same colour (black). 
Diagnostic Use ofHair Analysisfor the Detection ofMisuse ofAmfetamines and Cannabinoids 
Chapter six: Case studies Page 122 
This study was an initial attempt to provide information about the accuracy of self reports 
by analysing hair samples. All hair samples from individuals reporting to have abused 
Fenethylline were positive for AF showing that this was a reliable method for showing 
previous use and could be used to complement urine testing. Overall, this study indicated 
that there was a lack of correlation between self reported use and concentration of AF in 
hair. This will be partly due to varying dosages of the drug within tablets. 
Hairl8 (Table 6.3) was obtained from a different source. Case details were unknown for 
this particular sample. However, the hair sample was found to be positive along the length 
for AF indicating regular exposure. 
Postmortem blood samples were analysed by Forensic Medicine and Science at University 
of Glasgow for amfetamines and related compounds. Chronic arnfetamine or ecstasy 
abuse was confirmed by the results of the hair analysis. In many of these cases regular use 
was not known. The postmortem hair samples were positive for these drugs and in general 
the results showed that there was good qualitative correlation between blood and hair 
results. In some cases these were also supported by evidence in the police report. 
Postmortem hair samples that were positive for MDMA were also positive for its break 
down product, MDA. All of these samples were also positive for AF. This may be a result 
of taking AF tablets or alternatively as an impurity in ecstasy tablets. All other 
amfetamines (MA and MDEA) gave negative results for hair samples. The concentration 
of AF in hair ranged from 0.04 - 4.42 ng/mg. The levels in hair ranged from 0.13-5.39 
ng/mg for MDMA and 0.04-0.78 ng/mg for MDA. The ratio of MDMA/MDA in the hair 
samples ranged from 3.25-11.10. In all of these cases the level of MDMA was higher than 
the level of MDA and it is likely the MDA is from the breakdown of MDMA. 
Out of the 6 postmortem hair cases that were analysed, ecstasy was known to be used in 2 
cases. Ecstasy use was not known for the other four cases, but MDMA and MDA were 
found in these blood and hair samples. The findings in the hair samples would tend to 
suggest regular use. The hair MDMA levels found in this study were similar to those that 
have been found in cases of known ecstasy users. It was reported that the concentration of 
MDMA from 15 regular users of MDMA and MA ranged from 1.20-12.6 ng/mg in lcra 
hair. These volunteers had consumed 1 to 4 tablets with varying doses in the last month 
[92]. Another study found MDMA concentrations ranging from 0.117-6.44 ng/mg in 20 
cases of known users [99]. 
The results are summarized in Table 6.4 and the chromatograms of the control sample for 
all five amfetamines and one of authentic sample for AF, MDA and MDMA are shown in 
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Figure 6.1, Figure 6.2, Figure 6.3, Figure 6.4, Figure 6.5, Figure 6.6, Figure 6.7 and Figure 
6.8 respectively. 
Table 6.3 Amfetamines concentration finding in hair and urine case Samples 
Case Sample 
HairCOI 
HairC02 
HairC03 
Hair04 
Hair05 
Hair07 
Hair08 
Hair09 
HairlO 
Hairl 1 
Hair12 
Hairl4 
Hair15 
Hairl6 
Hair17 
Hairl8 
AF 
Neg 
Pos 
Pos 
Pos 
Pos 
Neg 
Pos 
Pos 
Pos 
Pos 
Pos 
Pos 
Pos 
Pos 
Pos 
Pos 
Urine 
Cannabinolds 
Pos 
Neg 
Pos 
Pos 
Neg 
Pos 
N/D 
Pos 
Pos 
N/D 
Pos 
N/D 
Pos 
N/D 
Pos 
NID 
Hair n 
AF 
N/D: Not Done 
2.45 
1.64 
3.32 
2.49 
16.52 
0.65 (0-3 cm) 
0.22 (3-6 cm) 
0.39 (6-9 cm) 
0.19 (9-12 cm) 
0.17 (12-15cm) 
0.15 (15-18em) 
2.08 
11.12 
1.69 
4.73 
0.17 
41.25 
12.12 
12.37 
57.69 
0.53 (0-3 cm) 
0.3 (3-6 cm) 
0.46 (6-9 cm) 
Table 6.4 Amfetamines concentration finding in hair and blood in postmortem case Samples 
AF MA M DA MDMA MD EA 
Case Blood Hair Blood Hair Blood Hair Blood Hair Blood Hair 
Sample m /L ng/mg mg/L ng/mg mg/L ng/mg mg/L ng/mg mg ng/mg 
PMOI N/D 0.34 0.40 Neg 0.04 0.35 0.40 3.17 N/D Neg 
PM02 0.62 4.42 N/D Neg 0.05 0.78 0.45 5.39 0.45 Neg 
PM03 N/D 0.23 N/D Neg 0.02 0.21 0.36 2.33 N/D Neg 
PM04 N/D 0.04 N/D Neg 0.02 0.04 0.75 0.13 N/D Neg 
PM05 N/D 0.06 N/D Neg 0.12 0.31 0.07 1.85 N/D Neg 
PM06 N/D 0.13 N/D Neg 0.02 0.16 0.75 1.17 N/D Neg 
N/D: Not Done 
Table 6.5 The concentration of AF and the number of tablets 
No of table 
Low (1 -2 ) 
Medium (3-5) 
High >5 
Concentration of AF in hair 
2.08-3.32 
0.17-57.69 
12.12-16.52 
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6.3 Case Abstract 
Reference: HairC01 Sex: Male Age: 27 
Background circumstances: According to medical files and self report, this man had been 
using cannabis and fenethylline (captagon) tablets for more than three years. He smoked 5 
cigarettes and took I fenethylline tablet daily. 
Toxicology: 
Positive urine result for cannabinoids. 
Negative urine result for arnfetamine. 
0-3 cm hair segment: 
2.45 nanograms of amfetarnine per milligrams of hair. 
All other amfetamines (MA, MDA, MDMA and MDEA) analyses gave NEGATIVE 
results. 
Reference: HairC02 Sex: Male Age: 25 
Background circumstances: According to his medical files and self report, this man had 
been smoking cannabis and taking 3-4 fenethylline tablets daily for more than three years 
Toxicology: 
Negative urine result for cannabinoids. 
Positive urine result for arafetamine. 
0-3 cm hair segment: 
1.65 nanograms of amfetamine per milligram of hair. 
All other arnfetarnines (MA, MDA, MDMA and MDEA) analyses gave NEGATIVE 
results. 
Diagnostic Use ofHair Analysisfor the Detection ofMisuse ofAmfelamines and Cannabinoids 
Chapter six: Case studies Page 129 
Reference: HairC03 Sex: Male Age: 38 
Background circumstances: According to his medical files and self report, this man had 
been smoking 1 cannabis cigarette daily for more than ten years. He had also been taking 
1 fenethylline tablet daily for more than five years. 
Toxicology: 
Positive urine result for cannabinoids. 
Positive urine result for amfetamine. 
0-3 cm hair segment: 
3.32 nanograms of amfetamine per milligram of hair. 
All other arnfetarnines (MA, MDA, MDMA and MDEA)analyses gave NEGATIVE 
results. 
Reference: Hair04 Sex: Male Age: 24 
Background circumstances: According to his medical report and self report, this man had 
been smoking cannabis daily for more than seven years and taken fenethylline tablets for 
more than eight years. He also used alcohol occasionally. 
Toxicology: 
Positive urine result for cannabinoids. 
Positive urine result for amfetamine. 
0-3 cm. hair segment: 
2.49 nanograms of amfetamine per milligram of hair. 
All other amfetamines (MA, MDA, MDMA and MDEA) analyses gave NEGATIVE 
results. 
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Reference: HairO5 Sex: Male Age: 32 
Background circumstances: According to his medical files and self report, this man had 
been using 7 tablets of fenethylline daily for more than two years. 
Toxicology: 
Negative urine result for cannabinoids. 
Positive urine result for amfetamine. 
0-3 cm hair segment: 
16.52 nanograms of amfetamine per milligram of hair. 
All other amfetarnines (MA, MDA, MDMA and MDEA) analyses gave NEGATIVE 
results. 
Reference: Hair07 Sex: Male Age: 27 
Background circumstances: According to his medical files, emergency room assessment 
and self report this man had been using cannabis for more than six years and had taken 
fenethylline tablets and used alcohol at intervals. He had smoked 3-5 cigarettes daily. A 
long strand of hair was collected and cut into six segments (0-3,3-6,6-9,9-12,12 -15 and 
15-18 cm). 
Toxicology: 
Positive urine result for cannabinoids. 
Negative urine result for amfetamine. 
0- 18 cm hair segment: 
0.65 nanograms of amfetamine per milligram of hair in 0-3 cm segment. 
0.22 nanograms of amfetamine per milligram of hair in 3-6 cm segment. 
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0.39 nanograms of amfetarnine per milligram of hair for 6-9 cm segment. 
0.19 nanograms of amfetamine per milligram of hair for 9-12 cm segment. 
0.17 nanograms of amfetamine per milligram of hair for 12-15 cm segment. 
0.15 nanograms of amfetamine per milligram of hair for 15-18 cm segment. 
All other arnfetarnines (MA, MDA, MDMA and MDEA) analyses gave NEGATIVE 
results. 
Reference: HairO8 Sex: Male Age: 32 
Background circumstances: According to his medical files and self report, this man had 
been using 2 tablets of fenethylline daily for more than two years. 
Toxicology: 
Positive urine result for arnfetamine. 
0-3cm hair seginent: 
2.08 nanograms of amfetarnine per milligram of hair. 
All other arnfetamines (MA, MDA, MDMA and MDEA) analyses gave NEGATIVE 
results. 
Reference: Hair09 Sex: Male Age: 21 
Background circumstances: According to his medical files and self report, this man had 
been using cannabis more than three years and had taken fenethylline tablets for more than 
three years. He smoked 1-2 cannabis cigarettes daily and took 4-5 fenethylline tablets 
daily. 
Toxicology: 
Positive urine result for cannabinoids. 
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Positive urine result for ainfetarnine. 
0-3cm hair segment: 
11.12 nanograms of amfetamine per milligram of hair. 
All other amfetamines (MA, MDA, MDMA and MDEA) analyses gave NEGATIVE 
results. 
Reference: HairlO Sex: Male Age: 20 
Background circumstances: According to his medical files and self report, this man had 
been using cannabis for more than four years and had taken fenethylline tablets for more 
than four years. He had smoked 5 cigarettes daily and had taken 4-5 fenethylline tablets 
daily. 
Toxicology: 
Positive urine result for cannabinoids. 
Positive urine result for amfetamine. 
0-3cm hair segment: 
1.69 nanograms of arnfetarnine per milligram of hair. 
All other amfetamines (MA, MDA, MDMA and MDEA) analyses gave NEGATIVE 
results. 
Reference: Hairl 1 Sex: Male Age: 25 
Background circumstances: According to his medical files and self report, this man had 
been using 1-5 tablets of fenethylline daily for more than seven years. 
Toxicology: 
Positive urine result for amfetamine. 
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0-3cm hair seginent: 
4.73 nanograms of arnfetamine per milligram of hair. 
All other amfetamines (MA, MDA, MDMA and MDEA) analyses gave NEGATIVE 
results. 
Reference: Hair12 Sex: Male Age: 23 
Background circumstances: According to his medical files and self report, this man had 
been using cannabis for more than five years and fenethylline tablets for more than seven 
years. He had smoked daily and had taken 9 fenethylline tablets daily and used alcohol 
occasionally. 
Toxicology: 
Positive urine result for cannabinoids. 
Positive urine result for amfetamine. 
0-3cm hair segment: 
0.17 nanograms of amfetwnine per milligram of hair. 
All other amfetamines (MA, MDA, MDMA and MDEA) analyses gave NEGATIVE 
results. 
Reference: Hair14 Sex: Male Age: 34 
Background circumstances: According to his medical files and self report this man had 
been using 8-9 tablets of fenethylline daily for more than eight years. 
Toxicology: 
Positive urine result for amfetamine. 
0-3cm hair segment: 
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41.25 nanograrns of arnfetainine per milligram of hair. 
All other arnfetamines (MA, MDA, MDMA and MDEA) analyses gave NEGATIVE 
results. 
Reference: HairI5 Sex: Male Age: 35 
Background circumstances: According to his medical files and self report, this man had 
been using cannabis more than one year and had taken fenethylline tablets for more than 
three years. I cigarette was smoked daily and he had taken 2-3 fenethylline tablets daily 
and used alcohol occasionally. 
Toxicology: 
Positive urine result for cannabinoids. 
Positive urine result for amfetamine. 
0-3cm hair segment: 
12.12 nanograrns of amfetamine per milligram of hair. 
All other amfetamines (MA, MDA, MDMA and MDEA) analyses gave NEGATIVE 
results. 
Reference: Hairl6 Sex: Male Age: 40 
Background circumstances: According to his medical report, this man had been using eight 
tablets of fenethylline daily for more than fifteen years. 
Toxicology: 
Positive urine result for amfetamine. 
0-3cm hair segment: 
12.37 nanograms of Amfetarnine per milligrmn of hair. 
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All other amfetamines (MA, MDA, MDMA and MDEA) analyses gave NEGATIVE 
results. 
Reference: Hair17 Sex: Male Age: 26 
Background circumstances: According to his medical files and self report, this man had 
been using cannabis for more than ten year and he had taken fenethylline tablets for more 
than ten years. 2 cigarettes were smoked daily, 3-4 fenethylline tablets were taken daily 
and alcohol was used at intervals. 
Toxicology: 
Positive urine result for cannabinoids. 
Positive urine result for amfetamine. 
0-3cm hair segment: 
57.69 nanograms of arnfetamine per milligram of hair. 
All other arnfetarnines (MA, MDA, MDMA and MDEA) analyses gave NEGATIVE 
results. 
Reference: Hairl8 Sex: F Age: 9 
Background circumstances: This child had been given amfetamine by her mother. A 
neighbour called the police and they attended the house to find that the child was unwell 
and in need of medical treatment. At the hospital, she was treated accordingly and her 
urine was found to be positive for amfetamine. Hair samples were taken shortly afterwards 
to establish if there was any evidence of previous amfetamine use. 
Toxicology: 
Positive urine result for amfetamine. 
0-9 cm hair segment: 
0.53 nanograms of amfetamine per milligram of hair in 0-3 cm segment. 
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0.3 nanograms of amfetamine per milligram of hair in 3-6 cm segment. 
0.46 nanograms of amfetamine per milligram of hair in 6-9 cm segment. 
All other amfetamines (MA, MDA, MDMA and MDEA) analyses gave NEGATIVE 
results for all segments. 
Reference: PM01 Sex: Male Age: 28 
Background circumstances: This young man had a history of alcohol and heroin abuse and 
had at times been using methadone. He was on a number of medications including 
antidepressants. He returned to his house from a party and appeared to be intoxicated. He 
was left lying on a couch in the living room and was later found to be unresponsive. He 
was taken to hospital and was found to be dead on arrival. 
Cause of Death: Heroin and alcohol intoxication. 
Toxicology: 
0.4 milligrams of methamfetamine per litre of blood. 
0.04 milligrams of methylenedioxyamfetamine per litre of blood. 
0.4 milligrams of methylendioxymethylamfetamine per litre of blood. 
0.44 milligrams of citaloprain per litre of blood. 
0.02 milligrams of desmethyldiazepam per litre of blood. 
0.06 milligrams of codeine per litre of blood. 
0.1 milligrams of morphine per litre, of blood. 
16.71 milligrams of paracetamol per litre of blood. 
51 milligrams of alcohol per 100 millilitres of blood. 
215 milligrams of alcohol per 100 millilitres of urine. 
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0-3 cra hair segment: 
0.34 nanograms of amfetamine per milligram of hair. 
0.35 nanograms of methylendioxyamfetamine per milligram of hair. 
3.17 nanograms of methylendioxymethylamfetamine per milligram of hair. 
All other amfetarnines (MA and MDEA) analyses gave NEGATIVE results. 
Reference: PM02 Sex: Male Age: 30 
Background circumstances: This young man was known to abuse drugs but little was 
known about his medical history. He was found dead at his home seated on a chair 
slouched backwards, and beside him was a broken piece of mirror with white powder on it. 
Cause of Death: Arnfetarnine and MDMA (ecstasy) intoxication. 
Toxicology: 
0.62 nanograms of amfetamine per litre of blood. 
0.053 milligrams of methylendioxyamfetamine per litre of blood. 
0.45 milligrams of methylendioxymethylamfetamine per litre of blood. 
0.02 milligrams of diazepam per litre of blood. 
0.17 milligrams of benzoylecgonine per litre of blood. 
0.19 milligrams of methadone per litre of blood. 
0.020 milligrams of dihydrocodeine per litre of blood. 
0-3 cm hair segment: 
4.42 nanograrns of arnfetarnine per milligram of hair. 
0.78 nanograms of methylendioxyarnfetamine per milligram of hair. 
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5.39 nanograms of methylendioxymethylamfetamine per milligram of hair. 
All other arnfetarnines (MA and MDEA) analyses gave NEGATIVE results. 
Reference: PM03 Sex: M Age: 21 
Background circumstances: This young man had a history of alcohol abuse and took drugs, 
including ecstasy and diazepam. He was drinking heavily and smoking cannabis and 
subsequently went to bed. He was found lying on his back in bed, apparently dead. An 
ambulance was called but he was confirmed to be dead. 
Cause of Death: Methadone intoxication. 
Toxicology: 
0.02 milligrams of methylendioxyamfetainine per litre of blood. 
0.36 milligarns of mcthylendioxyrnethylarnfctamine pcr litrc of blood. 
0.08 milligrams of desmethyldiazepam per litre of blood. 
0.04 milligrams of diazeparn per litre of blood. 
0.19 milligrams of methadone per litre of blood. 
0.003 milligrams of dihydrocodeine per litre of blood. 
0.017 milligrams of morphine per litre of blood. 
0-3 cm hair segment: 
0.23 nanograms of amfetamine per milligram of hair. 
0.21 nanograms of methylendioxyamfetamine per milligram of hair. 
2.33 nanograms of methylendioxyrnethylainfetamine per milligram of hair. 
All other amfetamines (MA and MDEA) analyses gave NEGATIVE results. 
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Reference: PM04 Sex: M Age: 36 
Background circumstances: This man had a long standing history of drug abuse and was 
positive for hepatitis B. He was found lying on the floor, dead. An ambulance attended at 
the scene but there were no vital signs. An uncapped syringe was found lying close to him. 
Cause of Death: Heroin and temazepam intoxication. 
Toxicology: 
0.022 milligrmns of methylendioxyamfetamine per litre of blood. 
0.075 milligrams of methylendioxymethyl=fetamine per litre of blood. 
0.39 milligrams of oxazepam per litre of blood. 
12.55 milligrams of temazepam per litre of blood. 
0.021 milligrams of 6-monoacetylmorphine per litre of blood. 
0.164 milligrams of codeine per litre of blood. 
0.984 milligrams of morphine per litre of blood. 
0-3 cm hair segment: 
0.04 nanograms of arnfetarnine per milligram of hair. 
0.04 nanograms of methylendioxyamfetamine per milligram of hair 
0.13 nanograms of methylendioxymethylamfetamine per milligram of hair. 
All other amfetamines (MA and MDEA) analyses gave NEGATIVE results. 
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Reference: PM05 Sex: M Age: 40 
Background circumstances: This man returned home apparently drunk and continued 
drinking at home. The following morning he was found to be unresponsive and not 
breathing. Subsequent searching of his clothing revealed a single white tablet in one of the 
pockets, possibly thought to be ecstasy. 
Cause of Death: MDMA (ecstasy) and arnitriptyline intoxication. 
Toxicology: 
0.12 milligrams of methylendioxywnfetamine per litre of blood. 
0.075 milligrams of methylendioxymethylamfetamine per litre of blood. 
0.04 milligrams of desmethyldiazepam per litre of blood. 
0.04 milligrams of diazeparn per litre of blood. 
0.36 milligrams of dihydrocodeine per litre of blood. 
24.74 milligrams of paracetamol per litre of blood. 
3.12 milligrams of arnitriptyline per litre of blood. 
1.99 milligrams of nortriptyline per litre of blood. 
153 milligrams of alcohol per 100 millilitres of blood. 
260 milligrams of alcohol per 100 millilitres of urine. 
0-3 cm hair segment: 
0.06 nanograms of arnfetamine per milligram of hair. 
0.31 nanograms of methylendioxyamfetainine per milligram of hair 
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1.85 nanograms of mcthylendioxymcthylamfetaminc pcr milligrain of hair. 
All other arnfetamines (MA and MDEA) analyses gave NEGATIVE results. 
Reference: PM06 Sex: M Age: 19 
Background circumstances: This man had consumed a large amount of alcohol and was 
seen to consume a quantity of absinthe spirit (70% abv) and he appeared to become 
extremely drowsy and fell asleep. He was placed in a bedroom. Periodic checks were made 
on him but about an hour and a half after being put on the bed he appeared to turn blue. 
Despite resuscitation attempts he was pronounced dead. 
Cause of Death: Acute alcohol intoxication. 
Toxicology: 
0.02 milligrams of methylendioxyamfetamine per litre of blood. 
0.75 milligrams of methylendioxyrnethylamfetarnine per litre of blood. 
0.046 milligrams of lignocaine per litre of blood. 
350 milligrams of alcohol per 100 millilitres of blood. 
422 milligrams of alcohol per 100 millilitres of urine. 
0-3 cm hair segment: 
0.13 nanograms of amfetamine per milligram of hair. 
0.16 nanograms of methylendioxyamfetamine per milligram of hair 
1.17 nanograms of methylendioxyrnethylainfetamine per milligram of hair. 
All other arnfetarnines (MA and MDEA) analyses gave NEGATIVE results. 
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7 Conclusion 
Hair analysis has been shown to be effective in determining chronic use of drugs. This 
biological sample is advantageous in cases where it is suspected that urine specimens have 
been adulterated. Hair is difficult to adulterate, but if this is suspected then another sample 
can be requested easily. Amfetamines and cannabinoids are the two most abused 
substances in Saudi Arabia. For this reason a method to analyse both substances in hair 
simultaneously was investigated. Initial experiments showed that hair samples spiked with 
amfetamines gave good linearities using four different pre-treatment methods (alkaline pre- 
treatment using IM NaOH, fl-Glucuronidase using helix pomatia, methanol and acid pre- 
treatment using O. lM HCl) followed by SPE and GC-MS analysis. However, the 
recoveries of cannabinoids using these methods were poor as shown by the inability to 
detect low concentrations of standards. The recovery of these drugs using the SPE method 
alone without pre-treatment was investigated and was found to be acceptable for these 
substances. The alkaline pre-treatment method was then modified using different pH (5,6, 
7 and 8) of the phosphate buffer and four different eluents, acetone / chloroform (1: 1 v/v), 
hexane / EtOAc (9: 1 v/v), hexane / EtOAc (8: 2 v/v) and methanol to improve the 
cannabinoids (A? -THC and A? -THC-COOH) recovery. At the same time the amfetamines 
recoveries were monitored to ensure that their recoveries did not significantly decrease. 
Unfortunately the modified method demonstrated no significant improvement of 
cannabinoids recovery. A comparison study was carried out for the four pre-treatment 
methods to investigate which method gave the best recovery of amfetamine from hair 
using a hair case sample known to be positive for AF. This work showed that all four pre- 
treatment methods were effective in the extraction of AF from hair. However, it was 
shown that the best recovery for AF extraction was obtained using the 9- glucuronidase 
pre-treatment method. The method was successfully validated for all anifetamine 
compounds. 
To assess the validity of analysing hair samples for the presence of AF in victims of 
drowning, the change in concentration of AF in hair submerged in sea water and fresh 
water over a period of time was investigated. Ten amfetarnine positive hair samples were 
submerged in fresh and sea water for different periods of time. Six of these specimens were 
separated into 8 portions each. One of these portions was stored as an original specimen 
and 7 portions were immersed in 5 ml of sea water for 1,2 days, 1,2,3,4 or 8 weeks at 5 
OC. The other four specimens were separated into 5 portions, one of these portions was 
stored as an original specimen and 4 were stored in 5 ml of fresh water for 1,2,4 or 8 
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weeks at 5 T. The drug concentrations in the samples were monitored over this period. 
Hair samples were analysed using the validated method. The results showed a significant 
decrease of AF in hair with the time submerged in sea water. Fresh water had a much less 
significant effect over the study period. The decrease in hair AF concentration after one 
day in seawater ranged from 0.1-85% and after eight weeks ranged from 88-97%. Infresh 
water, after one week the concentration was found to decrease by 9-17% and after eight 
wccks by 16-60%. 
The incubation water used to submerge the samples after eight weeks was found to be 
positive for AF. The sea water contained a higher concentration of metal ions than the 
fresh water. The high concentration of metal ions in sea water may explain the increased 
rate of removal of AF from hair when compared to fresh water. 
Careful interpretation is required for hair samples obtained from victims of drowning. Sea 
water has the potential to cause the complete loss of drug from hair with increased time, 
while, fresh water may cause partial or possible complete loss with increased time. 
A total of 22 living and post-mortern cases samples were analysed by the validated 
method. Control hair samples were run simultaneously with case samples and their results 
were found to be within an acceptable range. This method is appropriate for the 
identification of amfetamines drugs in hair. Chronic amfetamine or ecstasy abuse was 
confinned by the results of the hair analysis. For all case samples, these results showed 
good qualitative correlation between self-reported use, urine or blood results and hair 
results for amfetamines. 
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7.1 Further Work 
In accordance with medical files and self reports of AF abusers involved in rehabilitation 
programs at Alarnal Medical Complex in Riyadh, Saudi Arabia, positive AF results were 
attributed to the illegal precursor of AF called fenethylline (captagon). The development 
of a method capable of detecting the parent drug, fenethylline and its metabolites AF 
simultaneously would be beneficial in order to discriminate between the source of AF. 
The extent of fenethylline use could then be recognized. Also, since theophylline is 
fenethylline metabolite, its identification may be of some use. 
Further work could be carried out on the AF stability study to include AF related 
compounds using different storage temperatures (refrigerator and freezer), different 
incubation times, different ionic strengths and different incubation conditions (dark, light, 
UV, pH). 
The proposed method requires further investigations to improve the cannabinoids 
recoveries to a satisfactory degree and to be able to include them in the method. More 
sensitive instrumentation would be beneficial to improve the cannabinoids detection in 
hair. 
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An investigation of the stability of amphetamine in hair samples submerged in a fresh 
and sea water environment. 
Fahad N. Bin-Eisa, Fiona A Wylie and John S. Oliver (Forensic Medicine and Science 
Department, University of Glasgow, Glasgow, United Kingdom) 
Abstract 
To assess the validity of analysing hair samples for the presence of amphetamine in victims 
of drowning, a method was first established to identify and measure the concentration of 
this drug in hair specimens. Amphetamine was extracted from hair using enzyme 
treatment with fl-Glucuronidase (helix, pomatia) at 45 T for 2 hours followed by solid 
phase extraction using Bond Elut Certify, mixed-mode columns. The samples were 
analysed by gas chromatography-mass spectrometry. An. HP-5 capillary column, 30 in x 
0.32 mm x 0.25 ýtrn film thickness was used and the temperature was programmed from 
100 to 300 T at a rate of 12'C / minute and held at 300 T for 5 minutes. The method was 
validated and found to be linear over the concentration range 5-200 nanogranis per 30 
milligrams of hair with a correlation co-efficient of 0.999. The limits of detection and 
quantitation were 2.7 nanogranis per 30 milligrams of hair and 4.3 nanograms per 30 
milligrams of hair respectively. Intra-day reproducibility had coefficients of variation of 
less than 10 % at 3 different analyte concentrations (10,50 and 200 nanograms per 30 
milligrams of hair). Inter-day reproducibility coefficient of variation was less than 15% 
and the recovery of the method was 71 %. 
The effect of salt water and fresh water on the concentration of amphetamine in hair 
specimens was investigated by splitting known amphetamine positive specimens. These 
were stored in these types of water at 5 OC for specific time intervals ranging from one day 
to eight weeks. The initial concentrations of the hair samples investigated ranged from 
0.14 to 57.70 nanograms per milligram of hair The results showed a significant decrease of 
amphetamine in hair with incubation time in salt water. The decrease in the different 
samples after eight weeks of incubation in salt water ranged from 60-95%. Fresh water had 
a much less significant effect over the study period. 
Keywords: amphetamine, hair, stability 
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